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ABSTRACT
Cattle, naturally infected with Mycobacterium 
paratuberculosis. were evaluated with respect to immune 
status. Their ability to express cell mediated immune 
responses to homologous and heterologous antigens was 
also evaluated. Lymphocyte and macrophage augmentation was 
attempted to localize the immune defect in cattle with 
paratuberculosis.
Infected cattle had varying responses to johnin skin 
test antigen. Lymphocyte blastogenic responses and 
migration inhibition were, however, consistently positive 
in infected cattle. Non-infected cattle had positive 
skin test reactions, blastogenic responses, and migration 
inhibition after sensitization with M^ bovis BCG, M. 
paratuberculosis. and keyhole limpet hemocyanin. No 
changes were seen in lymphocyte blastogenic response, 
migration inhibition, interleukin-2 production, and 
interleukin-1 release in infected cattle after 
sensitization.
Rifabutin treatment increased cutaneous 
hypersensitivity to johnin skin test antigen. No lesion 
alterations were induced with this antimicrobial 
agent.
Preliminary evidence indicated that blood monocytes 
phagocytize bacteria and take up ferritin. It could not be 
accurately determined if killing of the organism had 
taken place. The ferritin was seen in round clumps 
suggestive of secondary lysosomes and as small grains in 
association with bacteria. This may have represented 
phagosome-lysosome fusion. Interleukin-2 production 
was decreased in infected cattle from that in non­
infected controls. Non-infected cattle significantly 
increased interleukin-2 production in response to 
sensitizing antigens while no effect was seen in the 
infected animals.
Transfer factor specific for tL paratuberculosis and 
keyhole limpet hemocyanin augmented cell-mediated 
responses in infected cattle as evidenced by positive 
migration inhibition and increased interleukin-2 
production. No alterations in ileal and mesenteric lymph 
node lesions were noted after transfer factor treatment.
Blood monocytes from infected cattle spontaneously 
released high levels of interleukin-1 and increased 
release with bacterial lipopolysaccharide stimulation. 
Non-infected cattle released significant levels with 
keyhole limpet hemocyanin, M;_ bovis PPD, and johnin with 
the highest release occurring with johnin stimulation.
x
Interleukin-1 release was not affected by sensitization 
with bo vis BCG, Mj_ paratuberculosis and
keyhole limpet hemocyanin.
CHAPTER 1
LITERATURE REVIEW AND OBJECTIVES
General
Bovine paratuberculosis is a chronic debilitating 
enteric infection of ruminants caused by the acid-fast 
bacillus Mycobacterium paratuberculosis. The disease was 
first described by Johne and Frothingham in 1895,1 hence 
the name, Johne's disease. The organism was first 
isolated by Twort in 19102,3 and became named 
Mycobacterium enteriditis chronicae pseudotuberculosae 
bovis johne. The disease later became known as 
paratuberculosis or Johne's disease and the causative 
agent became Mycobacterium paratuberculosis.
Paratuberculosis occurs throughout the world and 
has a relatively wide host range. In addition to sheep 
and goats, numerous species of wildlife,4,5,6,7,8,9,10,11 
exotic animals,12,13,14,15,16,17,18,19,20 and non- 
conventional domestic animals17,21,22 have been infected. 
Monogastrics may also become infected under special 
circumstances.23-28 The organism may multiply in these 
hosts, but rarely results in clinical disease. The 
implication remains, however that these hosts may serve
1
as a reservoir for ruminant infection.
Paratuberculosis was first described in North 
America m  1908^ and has since been observed in 
virtually every state. A 1983 abattoir survey of 1000 
cattle in Wisconsin showed histologic lesions of Johne's 
disease in 11% of the animals examined. 3(^ In a New 
England-based study a prevalence rate of 18% was shown by 
employing culture techniques in addition to histologic
q i
evaluation.  ^ It was concluded that histologic 
evaluation alone was too inaccurate and insensitive. In 
a recent nationwide survey of 32 states and Puerto Rico,
non
Merkal et al^i£ examined lymph node specimens from 7,540 
animals by culture methods and found an overall 
prevalence of bovine paratuberculosis of 1.6%. The 
prevalence in dairy and beef cattle was determined to be 
2.9% and 0.8%, respectively. It has been estimated that 
losses for the dairy industry in the United States exceed 
$1.5 billion per y e a r . 3 ^
Animals are usually infected at less than 30 days of 
age and evidence by experimental inoculation suggested 
that cattle must become infected during calfhood in order 
to develop clinical disease because of the development of 
age-related resistance.33-43 It is estimated that only 
one-third of the exposed animals ever become infected.44 
Development of disease is dependent on the size of the 
exposure dose and the immunologic status of the host.44
Animals infected as adults may develop less obvious 
lesions or eliminate the organism.44 Experimentally 
infected animals have been reported to
recover.37'43'45'46 Some animals exposed to the organism 
never develop clinical disease, but may become carriers 
and shedders of the organism.44
The Channel Island and Shorthorn breeds appear to 
have the greatest incidence of infection among cattle.47 
In Louisiana, however, the Brahman is frequently 
infected. This may be simply due to the larger number of 
Brahman and Brahman-cross cattle in Louisiana versus 
Channel Island breeds.
Ingestion of feces containing high number of bacteria
AO
is the primary source of infection for the neonate. °
Once ingested the organism penetrates the intestinal 
mucosa through Peyer's patches.4^-51,225 o r g a n j_sm  is
then phagocytized by macrophages and survives 
intracellularly where it is protected from humoral 
factors. A multifocal to diffuse granulomatous lesion 
develops in the intestine and regional lymph nodes. 
Terminally a bacteremia and anergy develops.44 
Bacteremia can also develop in infected animals by 
desensitization with johnin.52 The organism has been 
recovered from testes,53 semen,53-55 bulbourethral 
gland,54 prostate,54'55 seminal vesicles,54'55 mammary 
gland,57-59 uterus,58'60-62 and the fetus.61-64 Because
of these observations, congenital infections have been
postulated. However, in a study by Merkal et al.,65 75%
of infected animals within a herd came from noninfected
dams. During anergy, the organism may invade the
cotyledons and result in abortion.66 Transuterine
infection with subsequent development of paratuberculosis
has not been documented.44 As many as 7% of infected
animals shed the organism in the m i l k . ^ '66• This may
also serve as a significant source of infection in young
animals in addition to contaminated feces which may
ftcontain greater the 10° organisms per gram.
Paratuberculosis is a slow spreading disease
requiring an extended period of time for the development
of clinical signs. Herds consequently become infected
before the disease is recognized in individual animals.
It has been shown that by the time the first infected
animal is recognized, 38%-42% of the herd is infected.67- 
7 0 Annual death losses within a herd may be as high as 
3%-10%. Clinical disease is usually associated with 
adult (>2 years) animals, however clinical disease has 
been seen in animals as young as 4 months of age.7-1- 
Parturition, a low plane of nutrition, high milk 
production, parasitic infection, grazing on mineral- 
deficient low lying wetlands, and various other stress 
factors have been incriminated in precipitating clinical 
disease.7^-76
Clinical Signs
Clinical signs usually begin as a nonresponsive, 
chronic or intermittent diarrhea. Periods of apparent 
remission occur which may last for weeks or months. 
Diarrhea subsides and weight gains occur during 
pregnancy, however at parturition diarrhea resumes, 
often more severe than previously.^ There may be 
intermittent fever, however appetite is usually good. 
During the terminal stages of the disease the diarrhea 
may become bloody, there is loss of appetite, emaciation, 
ventral edema, and death.
It has long been known that clinical signs and the
71 —7 6severity of the lesions rarely correspond. In
cattle the lesion is characterized as a diffuse 
granulomatous change, without necrosis, hyperemia, or 
reactionary fibrosis.76-79 Primary lesions are confined 
to the intestinal tract and regional lymph nodes, but 
there may be effusion into body cavities, serous atrophy 
of fat, and subcutaneous edema in the dependent areas of 
the carcass. The intestine is usually thickened, 
corrugated and highly folded. The folds remain when the 
segments of gut are stretched. In animals infected with 
pigmented strains of Mycobacterium paratuberculosis the 
intestinal mucosa may take on a yellow-orange hue.79-6  ^
Lesions may be found from the duodenum to rectum, but are
most common in the terminal ileum. In younger animals 
there may be no intestinal thickening, instead a
0*3
hemorrhagic enteritis occurs. J In regional mesenteric 
lymph nodes there is a granulomatous lymphadenitis with 
marked lymph node enlargement. Mesentric lymphatics may 
also be prominent. Lesions occasionally occur in other 
organs with the liver being the most common secondary 
organ affected.76'84
Pathology
Histologically the affected intestine contains 
numerous foamy macrophages within the lamina propria and 
occasionally in the submucosa. Early lesions appear 
tuberculoid (nodular) and rapidly coalesce to become 
lepromatous (diffuse).44 Langhans' type giant cells may 
or may not be a prominent feature. Acid-fast stains 
reveal the presence of numerous bacilli within the 
macrophages and giant cells. Occasionally, the bacilli 
are sparse or may not be evident at all.76,78'86"87 The 
earliest lesions seen in experimentally infected calves 
are focal aggregates of macrophages in Peyer's patches 
and in the villus tips.69"5  ^ Mast cell mediated 
enteropathy of the cranial portions of the intestinal 
tract is likely to be another feature in the early stages 
of paratuberculosis.88
In regional lymph nodes there are multifocal
accumulations of macrophages and giant cells primarily 
within the cortex. These nodular accumulations 
frequently coalesce. Acid-fast bacilli are usually 
demonstrable in these aggregates as well.
In the liver there may be multifocal granulomas and/or 
pericholangitis. Acid-fast bacilli are usually not 
observed in hepatic lesions.78'84
Intimal fibrosis and mineralization occur in the 
abdominal aorta and heart88'87'89. A fibrinoid or 
amyloid-like substance may be present in small vessels of 
lymph nodes, adrenals, udder, and renal glomeruli.44 
Neurologic lesions such as degenerative changes in 
the sciatic nerves and brachial plexus resembling 
lepromatous leprosy have been reported.89 Acid-fast 
bacilli are also present in these lesions.
Diagnosis
The antemortem diagnosis of paratuberculosis is 
hindered by the absence of sensitive tests. It should be 
kept in mind that immunologic methods give an indication 
of exposure and not infection and to distinguish between 
resistant and infected animals may be impossible using 
immunologic methods. Numerous diagnostic methods have 
been employed. These include intradermal and 
intraveneous johnin tests, complement fixation, 
hemagglutination, agar gel immunodiffusion, enzyme-linked
immunosorbent assay (ELISA), radioimmunoassay, 
fluorescent antibody, lymphocyte transformation, 
migration inhibition, leukocyte migration, 
immunoperoxidase, mucosal and lymph node biopsy, and 
fecal culture.44 None of these tests have proven to be 
completely accurate, providing variable percentages of 
false negatives and false positives. The available 
number of confirmed ELISA test results is too small to 
establish the accuracy of the test, but initial results 
are promising.90 It has been speculated that false 
positives only occur as the result of cross-reactivity 
with other mycobacteria and that such spurious results 
would be eliminated if pure and species specific antigens 
are utilized.44 This does not appear to be true because 
some animals develop a protective immunologic response, 
eliminate the organism, and become positive by serologic 
testing.44 These animals are then resistant to 
reinfection but continue to be serologically positive and 
should therefore not be culled, but be retained as 
breeding stock.
False negative results occur due to anergy9  ^or to 
antigen masking factors.92"95 The failure to respond to 
antigen usually occurs at the terminal stages of the 
disease, but anergy may occur at any time during chronic 
infection.44 In general, cell mediated immune responses 
are susceptible to tolerance.96 An animal which is
immunologically tolerant may react humorally but fails to 
develop an adequate cell mediated response. An initial 
serologically positive response with a subsequently 
negative cellular response may be interpreted as anergy 
in the infected state or following recovery from a 
previous infection.
Serologic testing on an individual animal basis is 
of little value. Most infected herds, however, have a 
prevalance of infection of 36%-42%.^ Therefore, testing 
10 out of 100 animals in an infected herd will result in 
a 98% probability for finding a positive response.
Although probably the most variable in its results 
and interpretation, intradermal johnin testing provides 
an easy and convenient method of diagnosis which can be 
used on the farm.®® The test is performed similar to 
tuberculin testing, except that results are read in 24-48 
hours in cattle. A change in skin thickness greater than 
5 mm is considered a positive test. Repeated tests can 
be performed at any time, but different sites must be 
used; apparently a local desensitization occurs at the 
site of injection.44,97,98
Intraveneous johnin tests provide greater accuracy 
than intrdermal testing, but requires 2-4 ml of
QQ
antigen. * A positive reaction is indicated by a febrile 
response or a change in the neutrophil:lymphocyte 
r a t i o . A  rise in rectal temperature of 1.5°C within
six hours post-injection is considered a positive 
response. A shift in the neutrophil:lymphocyte ratio 
greater than 2:1 at six hours post-injection is also 
considered a positive test result.
Microbiology
The only means by which a definitive etiologic 
diagnosis can be made is by cultivation of the organism 
either from feces or infected tissues. The organism is 
usually grown on Herrold's egg yolk media and 
identification is based on mycobactin dependence.®2 The 
suspected material should be innoculated on two slants, 
one with and one without mycobactin. Mycobactin P and 
mycobactin J will both support growth, however culture 
times are reduced from 8 weeks to 4-6 weeks by using 
mycobactin J.101 Mycobactin J is derived from 
Mycobacterium paratuberculosis Ames Strain 18 and 
enhances growth of strains which could otherwise not be 
cultured.101,102 Fecal cultures further complicate the 
isolation problem because of the necessity of 
decontamination. The feces (and contaminated tissue) are 
suspended in benzalkonium chloride to destroy saprophytic 
mycobacteria, fungi, and other bacterial contaminants 
prior to inoculation onto appropriate media.101,104 
Hexadecylpyridinium chloride at a concentration of 0.75% 
has also been used and may prove to be a more effective
decontaminant than benzalkonium chloride.105 Even with 
these decontaminating procedures, saprophytic overgrowth 
frequently occurs. Some isolates of Mycobacterium 
paratuberculosis are highly sensitive to the 
decontamination solutions.44 The minimum number of 
organisms shed in the feces which can be detected by 
fecal culture appears to be about 100 per gram of 
feces, however methods are available which can detect 
1 organism/gram of feces.®8
Vaccination and Treatment
Vaccines have been used in attempts to control the 
disease. A number of bacterins, both attenuated and 
unattenuated have been evaluated,118“121 In addition, 
heat-killed organisms,122-124 and disrupted fragments of 
Mycobacterium paratuberculosis117/124,125 have been used. 
The effectiveness of these vaccines has been disputed. 
However, the consensus is that vaccination will reduce 
the number of clinical cases, decrease the number of 
animals excreting the organism, and decrease the number 
of animals with detectable intestinal 
lesions.121/124/157/158 Vaccination does not confer 
absolute immunity as some vaccinates may develop disease 
or shed the organism.118/128/122-127
The main disadvantage to vaccination is that cattle
vaccinated with Mycobacterium paratuberculosis-origin 
bacterins develop hypersensitivity to johnin, avian PPD, 
tuberculin, and IXL_ bovis PPD.-*-2^  The vaccine is usually 
administered at 1-35 days of age and immunity lasts about 
18 months.12^-126 Revaccination is not recommended 
because of the possibility of decreased resistance 
following revaccination.#121,128
The paratuberculosis organism is susceptible to 
numerous antituberculous drugs in vitro, however 
treatments have not been successful.107-115 jn these 
attempts, animals frequently improve clinically, however 
continue to shed the organism and some animals eventually 
succumbed to the disease.
Immunoreactive Substances of Mycobacteria
The various species of mycobacteria have numerous 
similar chemical and adjuvant properties. All contain 
various mycosides, trehalose dimycolate, murmayl 
dipeptide, phosphotides, sulfatides, Waxes D, and water 
soluble adjuvants which make them unique from a 
immunological aspect. The most common factor in the 
mycobacterial component of Freund's complete adjuvant 
having immunoadjuvant activity is known to be N-acyl- 
muramyl-L-alanyl-D-isoglutamine, otherwise known as
1 9Qmuramyl dipeptide or MDP. The multiplicity of MDP
1 *30effects have been outlined by Masek. A pyrogenicity
effect of MDP was noted soon after its discovery. 
Somnogenicity, antinociceptivity, immunoadjuvanticity, 
anti-inflammatory, and hepatoprotective effects have been
-ion
also described. The target cell of MDP appears to be
-lOI
the macrophage. J± Lymphocyte proliferative responses 
seem to be secondary to the need for macrophages for T- 
cell activation.132“134,223,224
Another important adjuvant of mycobacterial origin 
is trehalose dimycolate or cord factor.135 The name 
’’cord factor" came from the observation that M. 
tuberculosis in culture formed serpentine cords in
parallel arrangements.13® Cord factor also has the
1 *37ability to activate macrophages^' and cause secretion of
mitogenic factors by mouse thymocytes in conjunction with
1 Rfiaddition of muramyl dipeptide. 0 Cord factor is
granulomagenic, probably by virtue of its 
IRQ 1 JO ■ 1 R7 1RRchemotactic # and stlmulant■L','' -LJO properties for 
macrophages and has antitumor properties.141
The mycosides are a diverse group of glycolipids 
which have become essential in serotyping organisms in 
the Mycobacterium avium-intercellulare-scrofulaceum 
complex. The mycosides of bovine origin are designated 
as mycoside B and are glycosylated phenolic phthicerol 
esters.143 Studies by Brennan and colleagues,143-145 
demonstrated that the glycosylated mycosides confer
antigenic and serologic specificity through an extremely 
small oligosaccharide. The same oligosaccharide has been 
identified from prototype strains of Mycobacterium 
paratuberculosis supplied by the National Disease Center 
in Ames, Iowa.-^^ The compound is also identical to a 
previously isolated oligosaccharide from a strain of Mj_
9 1 0  91  A
avium^1J• and it has been suggested that M. 
paratuberculosis may in fact be a specific ]yL_ avium
9 1  o
serotype. ■LJ Additional studies by McFadden and others 
have shown that M^_ avium and paratuberculosis can be 
distinguished on the bases of differences in their 
restriction fragment length polymorphisms.215 Recently 
lipoarabinomannan and lipid free arabinomannans have been 
shown to be potent immunoreactive substances of 
mycobacteria and in particular Mycobacterium 
paratuberculosis, and these antigens have been used with 
considerable success in enzyme immunoassays for Johne's 
disease.218
Immunology of Paratuberculosis
There is a paucity of information on the cellular 
immunology of Johne's disease compared to tuberculosis or 
leprosy. The clinical signs in cattle affected with 
Johne's disease have been postulated to result from an 
allergic response to products of the o r g a n i s m . I t  is
speculated that an antigen-antibody reaction in the 
infected tissue may cause the release of significant 
amounts of histamine resulting in diarrhea.62 The 
reaction of antigen with competent lymphocytes would then 
cause the release of nonspecific pyrogen and cytotoxins 
resulting in a febrile response, anemia, and emaciation. 
With these speculations in mind, Merkal and Witzel used 
whole blood, white blood cells, plasma, and febrile 
plasma to passively transfer johnin hypersensitivity to 
noninfected calves.146 All blood elements except for 
non-febrile plasma were able to confer johnin 
hypersensitivity with temporary fever and diarrhea.
Plasma factors which suppress in vitro lymphocyte
transformation have been identified in lepromatous
147 148leprosy and paratuberculosis. in addition, in
lepromatous leprosy there is an extensive replacement of 
paracortical areas in regional lymph nodes by 
histiocytes.149 A similar replacement also occurs in 
Johne's disease. Therefore, it appears that the 
destruction of paracortical areas in lymph nodes may 
result in the inability to mount an effective immune 
response.
Crohn's disease is a chronic inflammatory condition 
of the intestinal tract which affects humans. 
Histologically, the intestinal lesions are composed of a 
diffuse, intense accumulation of macrophages in the
lamina propria and submucosa, not unlike bovine 
paratuberculosis. For years, the cause of Crohn's 
disease has been unknown, however recently a 
mycobacterium has been isolated from several clinical 
cases.216 The mycobacterial agent has been identified as 
M. paratuberculosis.216•21  ^and through the use of DNA 
probes has been shown to be indistinguishable from the 
Johne's bacillus.216
Cattle affected with Johne's disease should provide 
an excellent model for the study of the pathogenesis of 
chronic intracellular infections. Due to the 
similarities of the various mycobacterial organisms and 
the similarities in disease conditions, particularly 
lepromatous leprosy, Crohn's disease and Johne's disease, 
it can be postulated that there may also be similarities 
in the cellular immunology.
Cellular Immunologic Events in Mycobacterial Infections
Although cellular immunity has only been 
superficially examined in Johne's disease, it has been 
closely examined in other mycobacterial diseases. It 
remains to be shown whether many of the observations 
noted in other mycobacterial diseases may also apply to 
Mycobacterium paratuberculosis infections.
Initial cellular events following the introduction of 
mycobacterial antigen involve presentation of antigen to 
appropriate lymphocytes. Accessory cells such as 
resident macrophages, dendritic cells, Langerhans cells 
and M cells provide this function. Resident macrophages 
may not be as important as other non-lymphoid accessory 
cells.150-152 jf major histocompatibility class (MHC) II 
antigens (la antigen) are expressed on both the 
accessory cells and T-lymphocytes, the foreign antigen 
can be adequately presented and invoke the release of 
soluble mediators such as interleukin 2 (IL-2) and gamma 
interferon. IL-2 is secreted by T-cells of the helper 
cell phenotype.153,154 Normally IL-2 secretion can be 
invoked by various plant lectins such as 
phytohemagglutinin, conconavalin A, or pokeweed mitogen 
and numerous antigens. Calcium ionophore A 23187 in the 
presence of phorbol myristate acetate has also recently 
been shown to be a potent inducer of IL-2 synthesis.
The IL-2 invokes increased IL-2 receptor expression and
proliferation of a suitable clone of T-lymphocytes 
(helpers, cytotoxic, and natural killers).156/157 
IL-2 also regulates and augments interferon production-1-3® 
which in turn is necessary for increased la antigen 
expression.33®'^®® Without la antigen expression, 
accessory cell and lymphocyte interaction do not occur.
In certain mycobacterial infections there is a decrease 
in macrophage la expression.163 Inhibition of IL-2 by 
muramyl dipeptide, a constituent of mycobacterial 
organisms, has been demonstrated.^®^ A decrease in 
IL-2 production may explain the paucity of lymphocytes in 
histologic lesions of chronic Johne's disease. 
Mycobacterium infected macrophages have also been shown 
to have decreased Fc receptor expression.-1-®3
It has been shown that lymphocytes incubated in 
vitro with mycobacterial antigens produce a population 
of lymphocytes that suppresses IL-2 production in normal 
lymphocytes. These antigens do not affect IL-1 
production by normal monocytes.^®3
Macrophage Function
The role and function of the macrophage in 
mycobacterial infections is controversial. Various 
research groups have obtained conflicting results. Much 
of this conflict may be due to the fact that most studies 
are performed on blood-derived macrophages or monocytes
instead of those mononuclear phagocytes actively 
participating in the local lesions.
Macrophages infected with mycobacteria have a 
decreased ability to kill other bacteria and phagocytize 
zymosan.164,165,226 In addition, it has been shown that 
phagosome-lysosome fusion is inhibited in mycobacterium- 
infected macrophages when intact organisms such as 
Bacillus subtilis and Mycobacterium avium are presented 
to the affected macrophage.188
There may be a decrease in oxidant metabolite 
production. In addition to being cytocidal to 
microorganisms, the oxidants produced by phagocytic cells 
are necessary for production of carbonyl radicals on the 
surface of lymphocytes which is a necessary prerequisite 
for the production of IL-2.187 Infected macrophages are 
also known to inhibit lymphocyte blastogenesis and 
lymphokine production.168 This activation may be 
inhibited by calcium channel blockers and calmodulin 
antagonists (i.e. acepromazine).169
Macrophages are responsible for IL-1 production 
which in turn stimulates T-cells to express receptors and 
secrete IL-2.170"178 In patients with lepromatous 
leprosy there is an increase in prostaglandin-E2 which is 
a potent inhibitor of IL-1 production^19. This can be 
demonstrated in vitro with M^ leprae stimulated 
macrophages from lepromatous individuals.174
Drutz et al has shown that leukocytes (monocytes, 
macrophages, and polymorphonuclear cells) from 
lepromatous and tuberculoid leprosy patients possess 
equivalent microbiocidal activity towards Listeria 
monocytogenes, E.coli, Proteus vulgaris, S. aureus, and 
Candida albicans.175 In addition, Ridel has shown that 
there is no difference in IL-1 production in lepromatous 
patients compared to healthy individuals.174 In Crohn's 
disease there appears to to an increase in IL-1 
production when induced and as a spontaneous 
phenomenon. ^  This implies a state of chronic 
activation or an inherent macrophage defect.
It has been documented that gamma-interferon is an
important activator of macrophages.17®-17  ^ Nogueira
demonstrated that peripheral blood lymphocytes of leprosy
patients fail to produce interferon and that production
1 ftOwas restored with the addition of purified IL-2.
Kaplan reported that macrophages from lepromatous 
leprosy patients were deficient in hydrogen peroxide 
production, but responded similarly to those from healthy 
individuals after the addition of interferon and that 
this effect was independent of prior macrophage ingestion 
of M.leprae bacilli.181 This study concluded that the 
immune defect was a lack of response to leprae by the 
patients' T-cells rather than a defective response of 
macrophages to interferon.
It has been shown in patients with lepromatous 
leprosy that there was no increase in C-reactive 
protein183. It is known that IL-1 is responsible for C- 
reactive protein production in acute phase inflammatory 
responses.183,184 Together these findings suggested that 
IL-1 production may also be decreased in mycobacterial 
infections.
Macrophage lysates from lepromatous leprosy patients 
have been shown to produce non-dialyzable antigen 
specific suppressor factors.185,186 Proliferation of T- 
lymphocytes and macrophages promoted by conconavilin A 
and other mycobacteria were inhibited by these lysates.
Natural killer cells were essential in tumor 
surveillance and and destruction of parasitized 
cells (macrophages).18^f188 Cytotoxic T-cells performed 
roughly the same function, however natural killer cells 
did not require MHC matching with target cells. In some 
mycobacterial infections, IL-2, which is important in 
killer cell proliferation, has been demonstrated to be 
deficient.189
In patients with lepromatous leprosy a decrease in 
the T4/T8 ratio in the lesions indicated a relative 
decrease in helper cell activity, therefore the cells 
necessary for IL-2 production were deficient in 
number.190 In addition, studies using anti-Tac antibody 
labeling have shown that there was a decrease in IL-2
receptor expression, but lymphocyte function could not be 
fully restored with the addition of exogenous IL-2 
alone191.
Immunomodulation
Dialyzable leukocyte extracts containing transfer 
factor augmented cellular and humoral immunity.193 
Transfer factor has been considered a portion 
of or the entire cell receptor for IL-2. Leprosy 
patients or paratuberculosis infected animals should 
benefit greatly from treatment with transfer factor. 
Supplementation with IL-2 may increase the immune 
response by reinstituting cellular proliferation of T- 
helper cells in those mycobacterial diseases in which IL- 
2 is deficient. Pharmacologic enhancement of macrophage 
function may lead to enhanced IL-1 production. This in 
turn may result in increased IL-2 receptor expression on 
lymphocytes193 and augmented proliferative and functional 
responses.
Since the discovery of transfer factor by 
Lawerence,19^'193 viable leukocytes, leukocyte extracts, 
or dialysates of leukocyte extracts have been used to 
transfer delayed hypersensitivity to previously naive 
individuals. Clinical syndromes treated with transfer 
factor have included cancer immunotherapy,196-198 
internal parasitism,199 lupus erythematosus,366
901  9 0 9sarcoidosis, vaccinia,
coccidiomycosis,20  ^ tuberculosis,20  ^ lepromatous 
leprosy205* and numerous others. The results have been 
variable, but were often favorable.
Leukocyte lysates which contained inducer factors 
(transfer factor) and supressor factors have been 
obtained from T-helper and T-suppressor cells, 
respectively.206 Much of the variability noted in 
clinical applications probably has been due to the fact 
that the crude lysates contained mixtures of both 
factors.207-210 The suppressor factor has also been used 
in the modulation of diseases such as lupus 
erythematosis200 and autoimmune thrombocytopenic 
purpura211 that are characterized by an undesirable 
immune response. Certain chemical and biological 
properties of transfer factor have been well 
documented206. In dialysates, the active component was 
present in the 3.5 to 12kD molecular weight range. 
Transfer factor binds to specific antigen and anti-la 
antibody. The product was absorbed by T-suppressor cells 
and macrophages. In addition, transfer factor equipped 
nonimmune cells with an antigen-binding moiety.206 It 
has been postulated that transfer factor may be a 
dialyzable fragment of a T-helper cell receptor206 
(possibly IL-2 receptor). The duration of effect of 
treatment with transfer factor has not been well
documented in every case. In a study using transfer 
factor as a preventative measure against varicella-zoster 
exposure, it was found that titers of treated, exposed 
patients who were protected from disease developed 
antibody titers that remained as high as those in 
infected individuals for 17 months.2 -^2 The transfer 
factor treated group also had an active cell mediated 
immunity as demonstrated by in vitro and skin tests for 
the same period of time.
In a study using transfer factor in 
lepromatous leprosy, donors for transfer factor were 
selected on the basis of positive skin reactivity and in 
vitro lymphocyte responses.205 Recipients were initially 
negative to skin tests using lepromin. After 
administration of transfer factor the recipients became 
skin test positive after the first or third days. In 
vitro testing of lymphocyte function (blastogenesis) was 
not altered. The recipients experienced erythema of the 
cutaneous lesions and occasionally fever. There was no 
alteration in histologic characteristics of the lesions 
when compared to pre-transfer factor lesions. The 
majority of the recipients reverted to a skin test 
negative status about 25 months after transfer factor 
administration. These changes, although shortlived were 
extremely promising when it is considered that only one 
injection of transfer factor was given.205 A multiple
dose trial appears indicated.
Chemotherapy
As previously stated, several anti-tuberculous drugs 
have been used to treat Johne's disease with little or no 
success. Clofazimine and isoniazid have been used most 
extensively although in a limited number of animals. 109 
A relatively new compound, Rifabutin (ansamycin LM 427), 
appeared promising.22* Preliminary results with 
rifabutin therapy in stump-tailed Macaques infected with 
M. paratuberculosis demonstrated remission of clinical 
signs and an extended life expectancy.219
Objectives
The exact nature of the immune defect in 
mycobacterial infections has not been determined 
Lymphocyte-macrophage interactions are extremely complex 
and difficult to dissect from one another. Transfer 
factor appears to augment lymphocyte function and not 
affect other aspects of cellular immunity. There are 
pharmacologic agents and other chemicals which augment 
monocyte/macrophage function with little or no effect on 
lymphocyte function. Proper macrophage function should 
also be restored if the infectious agent or antigen can 
be removed by an effective antimicrobial agent.
The objectives of this study were:
1. To determine the existence and nature of the cellular 
immune defect in cattle naturally infected with 
Mycobacterium paratuberculosis. Specific objectives 
included:
(a) Skin hypersensitivity to johnin, M^ bovis PPD, 
and keyhole limpet hemocyanin antigens.
(b) Lymphocyte blastogenic responses, macrophage 
migration inhibition factor production, interleukin-1 
release and interleukin-2 production in response to the 
skin test antigens.
2. To determine the response of cattle with chronic 
paratuberculosis and non-infected cattle inoculated with 
Mycobacterium paratuberculosis bacterin, live M^ _ bovis 
BCG, and keyhole limpet hemocyanin in Freund's incomplete 
adjuvant to the specific parameters outlined in objective 
1.
3. To determine the cell-mediated immune response in 
three naturally infected cattle with paratuberculosis 
using the assays outlined in objective 1 following 
weekly treatment for three weeks with specific transfer 
factor prepared to keyhole limpet hemocyanin and 
Mycobacterium paratuberculosis.
4. To determine the cell-mediated immune response in 
three naturally infected cattle with paratuberculosis 
using the assays outlined in objective 1 after daily 
treatment with 1200 mg rifabutin for three weeks.
5. To determine the extent of lesion alterations in 
ileal and ileocecal lymph nodes in the cattle described 
in objectives 3 and 4 before and after transfer factor 
and rifabutin treatment.
CHAPTER 2
LYMPHOCYTE BLASTOGENESIS AND MACROPHAGE MIGRATION 
INHIBITION IN CATTLE WITH CHRONIC BOVINE PARATUBERCULOSIS 
BEFORE AND AFTER SENSITIZATION WITH ML PARATUBERCULOSIS, 
M;. BOVIS AND KEYHOLE LIMPET HEMOCYANIN
Abstract
Cutaneous hypersensitivity, lymphocyte blastogenesis 
and macrophage migration inhibition in response to M. 
bovis PPD, johnin, keyhole limpet hemocyanin, and 
phytohemaglutinin were examined in 3 cattle naturally 
infected with Mycobacterium paratuberculosis and 3 non­
infected cattle. Infected cattle had variable response 
to the skin test antigens and largest blastogenic 
responses to Mj. bovis PPD also with positive responses 
to johnin. No significant blastogenic responses were 
seen with keyhole limpet hemocyanin in either group. 
Blastogenic responses with phytohemaglutinin were similar 
in both groups. The results of macrophage migration 
inhibition paralleled the lymphocyte blastogenic 
responses to the antigens and mitogen. Sensitization
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with bovis BCG, ML_ paratuberculosis, and keyhole 
limpet hemocyanin in Freund's incomplete adjuvant 
resulted in positive skin tests, blastogenic and 
migration inhibition responses in control cattle with M. 
bovis PPD, johnin, and keyhole
limpet hemocyanin and no change in the phytohemaglutinin 
responses. There was no difference in pre- and post 
sensitization blastogenesis and inhibition of migration 
data in infected cattle. There was, however, a 
significant decrease in johnin and M^ bovis PPD skin test 
reactivity and a failure to produce positive responses to 
keyhole limpet hemocyanin and Mj_ bovis PPD after 
sensitization.
Introduction
Bovine paratuberculosis is a chronic enteric 
infection caused by Mycobacterium paratuberculosis which 
results in diarrhea, weight loss and eventually death.8 
Numerous serologic tests for the antemortem diagnosis of 
paratuberculosis have been used with inconsistent
Q
results. Lymphocyte blastogenesis (LB) and macrophage
migration inhibition factor (MIF) assays have been
suggested as good in vitro indicators of the cell
mediated immune response.11*15,18 These assays have
also been used for the diagnosis of paratuberculosis.*'8- 
7,10,13,14,16
o
Anergy is known to occur in bovine paratuberculosis. 
Whether this anergy is complete or specific for only M. 
paratuberculosis has not been well characterized. In the 
this study, cell mediated immune responsiveness was was 
measured by skin testing and LB and MIF assays in cattle 
with chronic paratuberculosis before and after 
administration of sensitizing doses of M^ bovis BCG, M. 
paratuberculosis. and keyhole limpet hemocyanin (KLH). 
This was done to determine whether or not cattle infected 
with M^ paratuberculosis can distinguish between and 
mount a positive immune response to homologous and 
heterologous antigens as assessed by LB, MIF, and skin 
testing.
Materials and Methods 
Animals:
Three adult Brahman-cross cattle diagnosed positive 
for bovine paratuberculosis by rectal biopsy, ileal 
biopsy and by enzyme-linked immunosorbent assay.19 were 
donated to the Louisiana State University School of 
Veterinary Medicine by local cattle producers. These 
animals had a history of weight loss and intermittent 
diarrhea of at least one year, duration. In addition, 3 
healthy control cattle were selected at random from the 
School of Veterinary Medicine teaching herd to serve as 
controls. Fecal cultures from control animals using 
Herrold's egg-yolk media with and without 2 ug/ml
mycobactin J (Allied Labs, Ames,IA) were negative after 6 
months of incubation.
Media and Reagents
The culture medium used for the LB assays consisted 
of RPMI 1640 (GIBCO Laboratories, Chargin Falls, OH) 
supplemented with 4 mM L-glutamine and 10% fetal calf 
serum (FCS) without antibiotics (complete culture medium, 
COM). Dulbecco's MEM (GIBCO Laboratories, Chargin Falls, 
OH) was used in the MIF assay. Phosphate-buffered saline 
(PBS) was used as a washing solution. Phytohemaglutinin 
(PHA), keyhole limpet hemocyanin (KLH) (Sigma Chemical 
Co., St. Louis, MO), johnin and Mycobacterium bovis (M. 
bovis) PPD (Veterinary Services Laboratory, Ames, IA) 
were diluted to appropriate concentrations (as determined 
by previous dose response trials) in CCM. Mycobacterium 
bovis (Trudeau Institute, Saranac Lake, NY),
Mycobacterium paratuberculosis bacterin (Fromm 
Laboratories, Grafton, WI), and KLH in Freund's 
incomplete adjuvant (Sigma Chemical Co. St. Louis, MO) 
were used to sensitize both groups. Freshly prepared 
[3H ]thymidine in CCM was used to assess proliferative 
responses in blastogenesis assays.
Skin Testing
The cervical area of each cow was clipped and double
skin thickness measured prior to injection. Intradermal 
injections of 0.2 ml containing .1000 p.g johnin, M^ bovis 
PPD and KLH in PBS were given to each cow. For a 
negative control PBS was used. The change in double skin 
thickness was recorded after 48 hrs. The cattle were 
retested using the contralateral cervical area after 
sensitization. A change in skin thickness >5mm was 
considered a positive reaction.
Blood Mononuclear Cells
Heparinized whole blood was collected by venapuncture 
and diluted 1:1 with PBS. An equal volume of Histopaque- 
1.083 (Sigma Chemical Co., St. Louis, MO) was slowly 
injected underneath the blood using a 6 in, 18 ga needle. 
The blood-Histopaque gradient was centrifuged at 1000 X g 
for 45 min and the mononuclear cell band at the interface 
was removed and the cells washed three times with PBS. 
Platelet contamination was minimized by differential low- 
speed centrifugation during washing (250 X g for 10 min). 
Viability by trypan blue exclusion was >95%.
Lymphocyte Blastogenesis
Gradient-separated mononuclear cells were suspended 
in CCM at a concentration of 2 X 106/ml and 100 ul 
aliquots were placed in the wells of a 96 well 
microtiter plate. To triplicate wells was added 100 ul
of one of the following in CCM: 50 ug/ml johnin, 50 ug/ml 
M. bovis PPD, 30 ug/ml KLH, 25 ug/ml PHA, and CCM without 
additive. The cells were incubated for 72 hrs., pulsed 
with 0.5 uCi/50ul [3H ]thymidine, and collected 18 hrs 
later onto glass fiber disks using a semi-automated cell 
harvester (Skantron Inc., Sterling, VA). The disks were 
dried overnight at 60°C and placed in scintillation vials 
to which was added 3 ml of scintillation cocktail 
(Fluoralloy™ in toluene, Beckman Instruments, Fullerton, 
CA). The vials were placed in the dark overnight to 
minimize inherent chemiluminescence. Counts were made 
for 2 min on a Packard Tri-Carb 4640 beta counter 
(Packard Instrument Co., Downers Grove, IL). The data 
was expressed as the antigen cpm/media cpm stimulation 
index (SI). A SI > 2.0 was assigned as a positive 
response as previously determined.
Migration Inhibition Factor Assay
A microagarose droplet assay as described by 
Harrington and Stastny was used with minor 
modifications. Cell pellets containing 10® gradient- 
separated mononuclear cells were combined with 100 ul of 
2 X Dulbecco's MEM with 20% FCS and 100 ul melted agarose 
(SeaPlaque™, FMC Corporation, Rockland, ME). The cells, 
media and agarose were gently mixed and 1 ul droplets 
were placed in the center of the wells of a 96 flatbottom
well microtiter plate. The plate was refrigerated (4°C) 
for 10 min prior to the addition of antigens. To
triplicate wells 100 jil CCM was added containg one of the
following: 50 yg/ml johnin, 50 ug/ml ML_ bovis PPD, 50
p.g/ml KLH, 25 \ig/ml PHA and CCM without additive. After
48 hrs incubation each well was photographed and a 5 X 7 
was print made. The two most symmetrical droplets from 
each treatment were selected and the distance from the 
edge of the droplet to the edge of the cell migration 
zone was measured. Three random measurements were made 
from each of the selected droplets and the mean and 
standard error was calculated. Data were expressed as % 
inhibition of migration: [(mean migration distance of
media control) -(mean migration distance of 
antigen)/(mean migration distance of media control)] X 
100. A 20% inhibition was considered a positive MIF 
assay reaction.'
Sensitization
Infected and non-infected cattle were inoculated 
subcutaneously with 8.0 mg KLH in Freund's incomplete 
adjuvant, 1.0 ml heat-killed paratuberculosis bacterin 
(twice the recommended dose), and 6 X 10® MN_ bovis BCG. 
All assays were repeated 3 weeks after the sensitizing 
injections.
Statistics
Differences in stimulation indices and % inhibition 
of migration in both the infected and non-infected groups 
were tested using Student's t-test. A significant 
difference was considered to be P<0.05.
Results
Before sensitization two of three infected cattle had 
a positive skin test reaction to johnin (table 1).
Slight increases were seen with M.bovis PPD before 
sensitization and no significant changes were seen with 
KLH or the CCM control. No positive skin test reactions 
were seen in the non-infected group before sensitization 
(table 2). After sensitization the non-infected cattle 
had positive skin test responses to M^ _ bovis PPD, johnin, 
and KLH (table 2) while infected cattle had no positive 
skin test reactions to any of the antigens used (table 
1).
The LB assay was positive in all the infected animals 
before sensitization with johnin and M^ bovis PPD (table 
3). No positive responses were seen with KLH in either 
group. No significant (P>0.05) difference in PHA induced 
proliferation was seen in either group. After 
sensitization infected cattle showed no change whereas 
control cattle significantly (P<0.05) increased LB 
responses to all the sensitizing antigens (table 4). No
difference (P>0.05) in the PHA response was detected.
The results of the MIF (tables 5 and 6) assay 
paralleled the LB assay. Infecetd cattle had positive 
responses with IL bovis PPD and johnin before 
sensitization with no change after sensitization.
Control cattle significantly (P<0.05) increased responses 
to the sensitizing antigens. Stimulation with PHA 
consistantly produced a % inhibition of migration >98% in 
both groups of cattle.
Discussion
The LB and MIF assays used in this experiment were 
accurate indicators of chronic paratuberculosis. Skin 
testing with johnin and M^ _ bovis PPD were not reliable as 
previously indicated.8 After administration of 
sensitizing doses of M^ _ bovis BCG, M^ _ paratuberculosis, 
and KLH the control cattle developed positive skin tests, 
LB, and MIF assay reactions which were significantly 
different than pre-sensitization results. There was no 
change after sensitization in LB and MIF assays in the 
infected group, however there was a significant decrease 
in johnin skin test reactivity. It has been been shown 
that infected cattle can be desensitized with 
administration of johnin.8 This may account for the 
decrease in skin reactivity with johnin, but does not 
account for the failure to develop a positive skin
reaction to KLH and bovis PPD after sensitization.
The phenomenon of positive LB with concurrent negative 
skin test reactions as seen in this experiment has also 
been previously reported.10
The majority of previous studies using lymphocyte 
blastogenesis assays employed the whole blood 
technique.6,6,10,13 These studies revealed a significant 
number of false positives and negatives with marked 
individual variation. This has been attributed to serum 
factors in cattle with paratuberculosis which inhibit 
lymphocyte proliferation.9 Using a purified blood 
mononuclear cell assay improved the specificity of the 
technique markedly.2,16 In addition, heavily infected 
cattle have greater variation in LB than minimally 
infected cattle.10 Mycobacterial antigens other than 
johnin have been used in blastogenesis assays with 
varying results. In general Mycobacterium avium antigen 
provided equal or greater proliferative responses in 
infected animals6,13,16. It has been suggested that the 
LB assay can distinguish between KL_ paratuberculosis and 
M. bovis and that M^ avium infections can be 
differentiated from M^ bovis infections.2,16,17 The 
results of this experiment indicate that ML_ bovis PPD is 
a better test antigen in the detection of infected 
animals than johnin, and that this would make it 
impossible to distinguish between paratuberculosis and M^ _
bovis infections. The differences noted in these two 
mycobacterial antigens may be a reflection of different 
potencies of the preparations as the same absolute 
quantities were used.
In this experiment the LB and MIF assays have been 
demonstrated to be accurate immunologic tests for the 
antemortem diagnosis of bovine paratuberculosis. The 
unreliability of skin testing as a diagnostic tool has 
been further substantiated. Infected cattle fail to 
produce a positive cellular immune response to 
heterologous antigen at a dose shown to sensitize non- 
infected cattle.
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Table 1. Delayed Cutaneous Hypersensitivity 
in Mycobacterium partuberculosis Infected Cattle
Pre-Sensitization 
Change in Skin 
Thickness (mm)
Post-Sensitizati< 
Change in Skin 
Thickness (mm)
Antigen
Cattle 
#1 #2 #3
Cattle 
#1 #2 #3
PBSa 0.0 0.1 0.1 0.3 0.0 0.0
PPDb 2.3 3.8 3.6 2.2 1.9 3.0
johnin 3.5 11.1 9.8 2.7 2.1 3.2
KLHC 0.0 0.4 0.2 
mean+SD
0.2 0.2 
mean+SD
0.6
PBS 0.07+0.06 0.01+0.17
PPD 3.23+0.81 2.37+0.57
johnin 8.13+4.06* 2.67+0.55
KLH 0.20+0.20 0.33+0.23
aPhosphate buffered saline. 
^Derived from M^ bovis. 
cKeyhole limpet hemocyanin.
•f
Positive rection (>5mm increase).
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Table 2. Delayed Cutaneous Hypersensitivity 
in Healthy Control Cattle
Pre-Sensitization Post-Sensitization
Change in Skin Change in Skin
Thickness (mm) Thickness (mm)
Antigen
Cattle 
#1 #2 #3
Cattle 
#1 #2 #3
PBSa 0.2 0.1 0.0 0.4 0.1 0.0
PPDb 1.6 0.9 0.4 18.5 27.5 23.2
johnin 1.7 2.0 0.9 11.9 15.2 14.5
KLHC 0.0 0.2 0.3 6.3 9.7 11.4
mean+SD mean+SD
PBS 0.10+0.10 0.17+0.21
PPD 0.97+0.60 23.07+4.50*
johnin 1.53+0.56 13.86+1.74*
KLH 0.17+0.15 9.13+2.60*
aPhosphate buffered saline.
^Derived from bovis. 
cKeyhole limpet hemocyanin.
Significantly different than pre-sensitization (P<0.05).
Table 3. Lymphocyte Blastogenesis
in Mycobacterium partuberculosis Infected Cattle
Pre-sensitization Post-sensitization
Antigen cpm SIa cpm SI
media 773 1.0 460
1
• o
PPDb 8,039 10.1 4,278 9.7
johnin 5,101 7.0 2,346
00•
KLHC 1,391 1.5 828 1.4
PHAd 17,624 23.8 11,316 24.2
aThe mean SI was calculated by dividing the mean antigen 
cpm of triplicate assays from each of the 3 infected 
animals by the cpm of the media control. SD did not 
exceed 10% of the mean.
^Derived from IL bovis; ckeyhole limpet hemocyanin; 
dphytohemaglutinin.
All antigen and mitogen responses are significantly 
different than the media control (P<0.05). No 
differences are apparent between pre- and post­
sensitization data.
Table 4. Lymphocyte Blastogenesis
in Healthy Control Cattle
Pre-sensitization Post-sensitization
Antigen cpm SIa cpm SI
media 1,113 1.0 976 1.0
PPDb 1,001 0.9 5,270 5. 9*e
johnin 890 0.9 4,587 5. 0*e
KLHC 1,447 1.5 3,806 3. 7*e
PHAd 22,371 20.8e 21,765 22.0e
aThe mean SI was calculated by dividing the mean antigen 
cpm of triplicate assays from each of the 3 infected 
animals by the cpm of the media control. SD did not 
exceed 10% of the mean.
^Derived from bovis; ckeyhole limpet hemocyanin; 
dphytohemaglutinin.
Significantly different than pre-sensitization data 
(P<0.05).
eSignificantly different than media control (P<0.05).
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Table 5. Mean Percent Inhibition of Migration 
in Mycobacterium paratuberculosis Infected Cattle
Antigen Pre-Sensitization Post-Sensitization
PPDb 76.2+ 8.5a 72.4+9.3
johnin 56.6+6.6 59.1+7.7
KLHC 19.5+1.2 15.3+7.0
aMean+SE
^Derived from jML_ bovis; ckeyhole limpet hemocyanin. 
%inhibition of migration with phyohemalutinin exceeded 
98% in all assays.
A positive response is >20% inhibition.
No significant difference after sessitization.
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Table 6. Mean Percent Inhibition of Migration 
of Healthy Control Cattle
Antigen Pre-Sensitization Post-Sensitization
PPDb 11.7+ 3.2a 37.0+ 5.1*
johnin 8.0+ 4.3 33.6+ 4.0*
KLHC 5.5+ 2.8 23.8+ 4.6*
aMean+SE
^Derived from M^ _ bovis; ckeyhole limpet hemocyanin. 
Significantly different than pre-sensitization data 
(PC0.05).
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CHAPTER 3
INTERLEUKIN-1 RELEASE BY BLOOD MONOCYTES FROM 
CATTLE NATURALLY INFECTED WITH MYCOBACTERIUM 
PARATUBERCULOSIS
Abstract
Interleukin-1 (IL-1) release from blood monocytes 
was measured using a mouse thymocyte proliferation assay. 
Levels were determined in 3 cattle naturally infected 
with Mycobacterium paratuberculosis and 3 non-infected 
cattle. Release of IL-1 was measured before and after 
sensitization with heat-killed Mycobacterium 
paratuberculosis. live Mycobacterium bovis BCG, and 
keyhole limpet hemocyanin. Monocytes from infected 
cattle before in vivo sensitization spontaneously 
released high levels of IL-1 and increased IL-1 release 
in response to bacterial lipopolysaccharide. Non- 
infected cattle had increased IL-1 release when blood 
monocytes were stimulated with Mi. bovis PPD, 
lipopolysaccharide, and johnin. Johnin produced the 
greatest response. Release of IL-1 after sensitization 
was unaltered in both groups. These data suggest either 
a chronic state of activation in blood monocytes
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or a defective regulatory mechanism for IL-1 in cattle 
infected with Mycobacterium paratuberculosis.
Introduction
Bovine paratuberculosis (Johne's disease) is a 
chronic enteric infection caused by Mycobacterium 
paratuberculosis most often affecting ruminants.*1 The 
disease has a marked histopathologic resemblance to 
lepromatous leprosy and Crohn's disease and has been 
proposed as an animal model for Crohn's disease.28 Based 
on the similarity of the enteric lesions, it may be 
postulated that similar inflammatory and immunologic 
mechanisms occur in these diseases. Measurement of 
cytokine release and function in bovine paratuberculosis 
has been limited to the study of migration inhibition 
factor2 and indirect evaluation with lymphocyte 
blastogenic responses.6/13»14,19,21
Interleukin-1 (IL-1) produced by antigenic
stimulation of macrophages (M$) has many molecular forms 
1 7and functions.'1 Its relationship to a variety of 
different disease conditions has also been examined. 
Spontaneous release of IL-1 from blood monocytes, M$> or 
alveolar M$ has been noted in patients with 
sarcoidosis,20 tuberculoid leprosy,25 scleroderma,1 
tuberculosis,9 and Crohn's disease.20 In lepromatous 
leprosy blood monocyte-derived M$ fail to produce IL-1
initially, but can produce normal levels when 
cycloxygenase inhibitors, such as indomethacin, are added 
to the IL-1 producing blood c e l l s . T h i s  restoration 
effect was seen only in response to Mycobacterium leprae. 
In other disease conditions such as sarcoidosis, 
tuberculosis, and Crohn's disease, IL-1 was examined 
because of the central role of the M$ in the lesions of 
these diseases. In scleroderma, the principle lesion 
component is an overabundance of collagen with the M$ 
having only a minor role in lesion formation. However, 
examination of the role of IL-1 in this disease is also 
warranted because of its ability to induce fibroblast 
activation and proliferation,
The role of IL-1 in the pathogenesis of bovine 
paratuberculosis and an evaluation of host immune status 
has not been previously examined. As the M$ is the main 
cellular component in the lesions of paratuberculosis, 
the ability of blood monocytes to produce and release IL- 
1 in cattle with chronic paratuberculosis was measured. 
Alterations in IL-1 release were also measured after 
sensitization with Mycobacterium paratuberculosis (M. 
paraTB), Mycobacterium bovis (M. bovis), and keyhole 
limpet hemocyanin (KLH).
Materials and Methods
Animals:
Three adult Brahaman-cross cattle diagnosed positive 
for Johne's disease by rectal biopsy, ileal biopsy and by 
enzyme-linked immunosorbent assay as previously 
described.39 were donated to the Louisiana State 
University School of Veterinary Medicine by local cattle 
producers. These animals had a history of weight loss 
and intermittant diarhea for at least one year. Non- 
infected animals were selected at random from the School 
of Veterinary Medicine teaching herd to seve as controls. 
Fecal cultures from control animals incubated on 
Herrold's egg-yolk media with and without 2 ug/ml 
mycobactin J (Allied Labs, Ames,IA) were negative after 6 
months.
Media and Reagents:
Culture medium (RPMI 1640, GIBCO Laboratories,
Chargin Falls, Ohio) supplemented with 4mM L-glutamine 
and 2% heat-inactivated fetal calf serum (FCS) without 
antibiotics was used for cell cultures from which IL-1 
supernatants were prepared. Similar medium was used for 
the IL-1 assay with the addition of 10% FCS. Phosphate- 
buffered saline (PBS), pH = 7.4, was used as a washing
solution. Concanavalin A (Con A), KLH, Serratia 
marscecens LPS (Sigma Chemical Co., St.Louis, MO), johnin 
and bovis PPD (Veterinary Services Laboratory, USDA, 
Ames, IA), were diluted to the appropriate concentrations 
(as determined by previous dose response trials) in media 
with 2% FCS. Infected and non-infected cattle were 
inoculated subcutaneously with 8.0 mg KLH in Freund's 
incomplete adjuvant (Sigma Chemical Co., St. Louis, MO),
0.5 ml heat-killed M^ paraTB in oil (Fromm Laboratories, 
Grafton, WI), and 6 X 108 MU bovis BCG (Trudeau 
Institue, Saranac Lake, NY). In vivo sensitization was 
evaluated by skin test reactivity, migration inhibition, 
and blastogenic responses using the sensitizing antigens 
(Chapter 2).
Preparation of Monocytes:
Blood (40 ml) was collected using 50 U/ml 
preservative-free heparin (Sigma Chemical Co., St. Louis, 
MO) as an anticoagulant. After diluting the blood 1:1 
with PBS and equal volume of HistopaqueR (1.083 g/ml, 
Sigma Chemical, St. Louis, MO) was injected underneath 
the diluted blood using a 6 in, 18 ga needle. The blood- 
HistopaqueR gradient was centrifuged at 1000 X g for 45 
min and the peripheral blood mononuclear cell layer at 
the interface was harvested. Cells were washed three 
times in PBS and suspended at a final concentration of 8
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X 10®/ml in media with 2% FCS. Platelet contamination 
was minimized by differential low speed centrifugation 
during washing (250 X g for 10 min). The cells were 
incubated in a 75 cm2 plastic culture flask (15 to 20 ml 
per flask) for 1 h. Non-adherent cells were removed by 
vigorously washing 5 times with PBS. Adherent cells were 
removed using a plastic cell scraper and suspended in 
media containing 2% FCS at a concentration of 1 X 106/ml 
(trypan blue exclusion showed a viability of >90%). 
Recovered adherent cells consisted of >95% monocytes with 
slight platelet contamination. Aliquots of adherent 
cells (1ml) were placed in wells of a 24 well flat bottom 
plate (Corning Glass Works, Corning, NY).
Preparation of IL-1 Containing Supernatants:
To 1 ml of 1 X 10® adherent cells/ml from each 
animal was added equal volumes of the following; media 
with 2% FCS, 50 y.g/ml johnin, 50 ug/ml bovis PPD, 50 
ug/ml KLH, and 20 y.g/ml LPS. Cells were cultured for 24 
hrs at 37°C and 5% CO2. Supernatants were collected and 
maintained at -60°C until assayed (within 2 weeks).
IL-1 Assay:
The assay for IL-1 followed the guidelines as
1 ^reviewed by Gearing, et al with minor modifications. 
Adherent cell supernatants were thawed and serial two­
fold dilutions were made with media to 1:64. The 
thymuses from 6 wk old C3H/HeJ mice (Jackson 
Laboratories, Bar Harbor, ME) were used in all assays. 
Each thymus was aseptically removed and teased apart in 5 
ml of media. The thymocytes and thymic tissue were 
allowed to sediment at 1 X g for ten minutes. About 4 ml 
of cell suspension was withdrawn and adjusted to a final 
concentration of 5 X 106/ml in media containing 10% FCS 
and 1.5 ug/ml Con A. Viability assesed by trypan blue 
exclusion was >95%. 100 p.1 aliqouts of thymocytes were
added to the wells of a 96 flatbottom well culture plate. 
An equal volume of the varying dilutions of adherent cell 
supernatants was added to the thymocyte cultures. After 
incubation for 48 hrs, 0.5 y.Ci/50y.l [ ] thymidine in RPMI 
with 10% FCS was added to each well. Cells were 
harvested after 18 hr incubation onto glass fiber discs 
using a semi-automated cell harvestor (Skraton Inc., 
Sterling, VA). Glass fiber discs were dried overnight 
at 60°C, placed in scintillation vials and 3 ml of 
scintillation cocktail (Fluoralloy™, Beckman 
Instruments, Fullerton, CA.) was added. The samples were 
placed in the dark overnight to minimize inherent 
chemiluminescence before beta counting. Counts were made 
for two minutes on a Packard Tri-Carb 4640 beta counter
(Packard Instrument Co., Downers Grove, IL). All assays 
were performed in triplicate. Supernatants were initially
screened for interleukin-2 by means of a Con A-blast
97proliferation assay. '
Statistical Analysis:
Wilcoxon's rank sum test was used to identify 
treatment group differences in IL-1 release; a difference 
was considered significant at P<0.05.
Results
The concentration of IL-2 in the monocyte-derived 
supernatants was negligible by the Con A blast assay.
The results of the mouse thymocyte proliferation assay 
before sensitization are shown in Table 1. Supernatants 
obtained from media, KLH, bovis PPD, and LPS- 
stimulated monocytes induced thymocyte proliferative 
responses which were significantly (P<0.05) greater in 
the infected group than in noninfected controls. 
Proliferative responses produced by johnin stimulated 
monocyte supernatants were not significantly (P>0.05) 
lower in the infected group. The LPS-stimulated 
supernatants produced significantly (P<0.05) greater 
proliferative responses when compared to the media
control in both groups. The control group monocyte 
response was significantly (P<0.05) greater with johnin 
antigen when compared to the other antigens, although all 
treatments are significant (P<0.05) compared to responses 
obtained with the media control. The thymocyte 
proliferative responses with bovis BCG, paraTB, and 
KLH in the same groups of animals after sensitization is 
presented in Table 2. Although the cpm differed greatly 
before and after sensitization, stimulation indices for 
the IL-1 responses were remarkably similar. There was a 
significant (P<0.05) decrease in cpm values corresponding 
to all stimuli in both groups of animals. Stimulation 
with johnin remained significantly (P<0.05) higher in the 
non-infected group after sensitization. The infected and 
non infected groups had similar KLH and PPD responses.
Discussion
The lesions of bovine paratuberculosis typically 
reveal a marked infiltration of containing large 
numbers of Mj_ paraTB organisms in the lamina propria and 
submucosa of the small intestine and in the cortex and 
medulla of mesenteric lymph nodes. Disseminated disease 
is rare, but has been reported^'*1'1® and is felt to be 
the result of terminal anergy.*-1- As the is 
the main lesion component and provides a major initial 
defense mechanism against mycobacterial disease,
investigation in M$ function with respect to cytokine 
production and/or release seems warranted.
It has been shown that bovine blood monocytes and 
monocyte derived readily phagocytose paraTB, but
fail to kill the organism.5'3^ In other mycobacterial 
diseases, such as Mycobacterium leprae infections, M3> 
react similarly in that there is a failure to kill the 
organism or other phagocytosed organisms even when M. 
leprae-burdened macrophages are exposed to exogenous 
interferon gamma. ^
In this study the blood monocytes from paraTB 
infected cattle spontaneously release IL-1. This
phenomenon has been seen in other granulomatous diseases
1 o nsuch as scleroderma,* sarcoidosis, w tuberculoid
leprosy,35 and Crohn's disease.3® The similarities
between bovine paratuberculosis and Crohn's disease
extend beyond lesion morphology and spontaneous IL-1
release by blood monocytes. Recently a mycobacterial
agent has been isolated from several Crohn's 
1 n *3 ^patients. Three separate isolates have been shown
to be indistinguishable from M^ _ paraTB ATCC 19698 by 
using DNA probes which distinguish between mycobacterial 
species.26 The spontaneous release of IL-1 by alveolar 
MS> in sarcoidosis may be partially accounted for by the 
low levels of prostaglandin E2 (PGE2) produced by these 
cells m  vitro. Prostaglandin-E2 is a known
autoregulatory monokine of IL-1 production.15'24 In 
lepromatous leprosy the role of PGE2 in IL-1 regulation 
has been further demonstrated by restoration of IL-1 
release by addition of indomethacin to the assay 
system29. Although not examined in this experiment, 
defective or depressed production of arachidonic acid 
metabolites may be responsible for high spontaneous IL-1 
release from blood monocytes similar to that seen in 
alveolar in sarcoidosis.2
The intense thymocyte proliferative responses 
obtained by supernatants from johnin stimulated monocytes 
in the control cattle may be attributed to certain 
immunoreactive substances of mycobacterial origin known 
to be potent inducers of IL-1. Muramyl dipeptide is a 
constituent of most if not all mycobacterial cell walls 
which has been shown to induce IL-1.15'54 Trehalose 
dimycolate alone or in conjunction with muramyl dipeptide 
has also been shown to increase production of a thymocyte 
mitogenic protein,54 which is probably analogous to IL-
1. Increased (P<0.05) but lower response to ML bovis PPD 
than johnin may represent differing amounts of these 
immunoreactive agents in these two organisms, although 
this has not been substantiated.
Keyhole limpet hemocyanin is known to possess dose 
dependent mitogenic properties for murine lymphocytes25. 
This may account for the moderate responses seen in the
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control group with KLH. A second explanation, still to 
be demonstrated, may be that KLH shares similar properties with 
some phorbol esters. Phorbol esters such as 10-0- 
tetradecanoyl-phorbol-13-acetate have been shown to 
induce lectin-driven T-cell proliferation independent of 
accessory cells and i l-1.7'10'17'22
Sensitization was confirmed in the control cattle by 
positive intradermal reactions, lymphocyte blastogenesis 
(LB), and migration inhibition factor (MIF) assay 
(chapter 2). The infected cattle showed no evidence of 
sensitization using these methods, although the same 
doses of sensitizing antigen were used in both treatment 
groups. Anergy, known to occur in bovine 
paratuberculosis,4'11 may provide an explanation for in 
vivo sensitization failure in infected cattle.
On initial consideration it may be expected that if 
a positive response to a sensitizing antigen is obtained 
in LT and MIF assays, then an increase in IL-1 release 
should also be expected, however this is probably not the 
case. In a study by Chatila et al8 it has been shown 
that the necessary requirment for resting T-cell 
proliferation is contact by the accessory cell or 
monocyte. Interleukin-1 alone could not promote mitogen 
driven proliferation of purified T-cell cultures. With 
suboptimal concentrations of monocytes (0.1%), exogenous 
IL-1 increased lymphocyte proliferative responses in a
dose dependent manner. Higher concentrations of 
mononcytes, similar to that seen in peripheral blood, 
produced lymphocyte proliferative responses independent
O
of the concentration of exogenous IL-1. It was also 
shown that monocyte contact is essential for lymphocyte 
proliferation. This may be due to surface associated IL-
nc ,
l^J or possibly a currently unknown mechanism. In m  
vitro assay systems such as LT and MIF the necessary 
accessory cell-T-cell contact is established with optimal 
concentrations of monocytes and the results are not 
dependent on secreted IL-1.
The results indicate that there may be an abnormal 
regulatory mechanism for IL-1 secretion in bovine 
paratuberculosis. This may reflect abnormalities in 
arachidonic acid metabolism or some other cytokine yet to 
be identified as a modulator of IL-1. Alternatively 
spontaneous IL-1 release may be the result of chronic 
activation due to the large antigenic burdens in cattle 
infected with WL_ paraTB.
TABLE 1. Mean Mouse Thymocyte Proliferation By Monocyte 
Supernatants In The Presence Of Con A 
Before Sensitization
Infected Group Noninfected Group
Antigen cpma SIb cpm SI
media 10,191 1.000 1,185e 1.000
johnin 8,158 0.866 17,172 14.501*e
KLH 13,363 1.299 8,080 6.786*e
PPD 12,250 1.210 7,391 6.235*e
LPS 24,222 2.400* 9,987 8.377*e
aData expressed is the mean cpm of triplicate assays from 
the 3 animals in each group. SD did not exceed 10% of the 
mean. Only data of the dilution which gave the highest 
cpm is shown (1:8).
bThe mean stimulation index (SI) was calculated by 
dividing the mean of each antigen cpm by the mean of the 
media control for each animal. SD did not exceed 10% of 
the mean.
ft
P<0.05/ media comparison. 
eP<0.05, group comparison.
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TABLE 2. Mean Mouse Thymocyte Proliferation By Monocyte 
Supernatants In The Presence Of Con A 
After Sensitization
Infected Group Noninfected Group
Antigen cpma SIb cpm SI
Media 2,257 1.000 453e 1.000
johnin 1,683 0.776 6,136 13.552*e
KLH 2,992 1.333 2,758 6.110*e
PPD 3,110 1.412 3,075 6.790*e
LPS 5,202 2.296 3,572 7.884*e
aData expressed is the mean cpm of triplicate assays form 
the 3 animals in each group. SD did not exceed 10% of the 
mean. Only data of the dilution which gave the highest 
cpm is shown (1:8).
bThe mean stimulation index (SI) was calculated by dividing 
the mean of each antigen cpm by the mean of the media 
control for each animal. SD did not exceed 10% of the 
mean.
P<0.05, media comparison. 
eP<0.05, group comparison.
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CHAPTER 4
INTERLEUKIN-2 PRODUCTION IN CHRONIC BOVINE 
PARATUBERCULOSIS
Abstract
Interleukin-2 (IL-2) production from peripheral blood 
mononuclear cells was measured in cattle naturally 
infected with Mycobacterium paratuberculosis and in 
healthy control cattle using a Concanavalin A induced 
blast cell proliferation assay. Production of IL-2 was 
significantly reduced in infected animals when peripheral 
blood mononuclear cells were stimulated with Con A. 
Animals were sensitized with paratuberculosis 
bacterin, live Mj_ bovis BCG and keyhole limpet hemocyanin 
in Freund's incomplete adjuvant and IL-2 production re­
evaluated. Infected animals showed no difference in IL-2 
production after sensitization while healthy animals 
significantly increased production to the sensitizing 
antigens. These data indicate that cattle naturally 
infected with Mycobacterium paratuberculosis have a 
decreased ability to produce IL-2 in response to Con A 
and that sensitizing doses of mycobacterial and foreign 
antigens do not increase IL-2 production in response to
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those antigens. Defective IL-2 production or the 
presence of suppressor substances may account for 
these observations and may contribute to disease 
persistance in these animals.
Introduction
Bovine paratuberculosis is a chronic enteric disease 
caused by infection with Mycobacterium paratuberculosis 
(M. paraTB).6 The disease is prevalant throughout the 
United States and results in significant economic 
losses.6'17 The host immune status with respect to 
production of soluble immuno-inflammatory agents 
(interleukins, interferons, prostanoids, etc.) has been 
ignored in paratuberculosis with the exception of in 
vitro assays such as migration inhibition1 and lymphocyte 
blastogenesis^'11,12 which measure cytokine production 
indirectly and not quantitatively. Quantitative analysis 
of these mediators should afford a better understanding 
of the disease and the immune defect responsible for 
persistance of infection.
Interleukin-2 (IL-2) is a soluble lymphokine which 
functions to enhance proliferative responses and clonal
c 7 q n -»
expansion of activated lymphocytes. '' ' :7,Z,-L Antigenic, 
mitogenic, or alloantigenic stimulation of lymphocytes 
results in IL-2 release and IL-2 receptor 
expression.6,26'20 Other serum factors such as
transferrin are required to drive IL-2 stimulated T-cells 
through the S-phase of growth.2/29 It aiso j l-2 which 
promotes transferrin receptor expression on activated T- 
cells.^
Maintainence of the proliferative response in 
activated T-cells serves as the basis for IL-2 assays.^ 
This feature has also been the important factor in recent 
advances in propagation of cloned T-cell lines with 
specific antigen reactivity and cells which selectively 
produce large amounts of specific lymphokines.3
91Bovine IL-2 has been characterized recently. A 
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and chromatofocusing revealed the 
presence of three active molecular species which support 
long-term growth of Con A or mixed lymphocyte reaction- 
activated bovine T-cells. Cortisol has also been shown 
to suppress IL-2 in the bovine both in vitro and in vivo.-* 
The following data represent an initial evaluation of IL- 
2 production in cattle with chronic paratuberculosis.
Materials and Methods 
Animals:
Three adult Brahman-cross cattle diagnosed positive 
for bovine paratuberculosis by rectal biopsy, ileal 
biopsy and by enzyme-linked immunosorbent assay31 were 
donated to the Louisiana State University School of
Veterinary Medicine by local cattle producers. These 
animals had a history of weight loss and intermittant 
diarrhea of at least one year. In addition, 3 non­
infected healthy cattle were selected at random from the 
School of Veterinary Medicine teaching herd. Fecal 
cultures from control animals using Herrold's egg-yolk 
media with and without 2 y.g/ml mycobactin J (Allied Labs, 
Ames,IA) were negative after 6 months incubation. A 
single healthy adult cow was selected at random as a 
blast cell donor for all IL-2 assays.
Media and Reagents
The medium used for all cell cultures consisted of 
RPMI 1640 (GIBCO Laboratories, Chargin Falls, OH) 
supplemented with 4 mM L-glutamine and 10% fetal calf 
serum (FCS) without antibiotics (complete medium). 
Phosphate-buffered saline (PBS), pH = 7.4 was used as a 
washing solution. Concanavalin A (Con A), Keyhole limpet 
hemocyanin (KLH) (Sigma Chemical Co., St. Louis, MO), 
johnin and Mycobacterium bovis (M. bovis) PPD (Veterinary 
Services Laboratory, Ames, IA) were diluted to 
appropriate concentrations in complete media. Freshly 
prepared [3H]thymidine in complete media was used to 
assess proliferative responses. Animals from both groups 
were sensitized by subcutaneous injections of 800 mg KLH 
in Freund's incomplete adjuvant (Sigma Chemical Co., St.
Louis, MO), 0.5 ml heat-killed MU. paraTB bacterin (Fromm 
Laboratories, Grafton, WI) and 6 X 108 live £L_ bovis BCG 
(Trudeau Institute, Saranac Lake, NY)
Blood Mononuclear Cells
Heparinized whole blood (40 ml) was collected by 
venapuncture and diluted 1:1 with PBS. An equal volume of 
Histopaque-1.083 (Sigma Chemical Co., St. Louis, MO) was 
slowly injected underneath the blood using a 6 in, 18 ga 
needle. The blood-Histopaque gradient was centrifuged at 
1000 X g for 45 min and the mononuclear cell band at the 
interface was harvested and the cells washed three times 
with PBS. Platelet contamination was minimized by 
differential low speed centrifugation during washing (250 
X g for 10 min). The cells were suspended in complete 
medium to a final concentration of 4 X 106/ml. Cell 
viability was >95% using trypan blue exclusion.
Preparation of IL-2 Containing Supernatants
Preparation and assay of IL-2 containing supernatants 
were performed by the method of Oldham et al with some 
modification.  ^ Mononuclear cells (2 ml) were placed in 
wells of a 24 well flat bottom plate (Corning Glass 
Works, Corning, NY). The cells from each animal were 
cultured with 200 y.1 of one of the following; 500 \ig/ml 
Con A, 100 ug/ml johnin, 100 ug/ml ML bovis PPD, 100
y.g/ml KLH and complete media. The cells were incubated 
in a humidified atmosphere for 1 hr at 37°C with 5% CO2. 
The cell suspensions were harvested (200 X g for 10 min) 
and the cells washed once with PBS (200 X g for 10 min) 
and resuspended in complete medium at a concentration of 
4 X 106/ml. The wells were rinsed twice with 3 ml of PBS 
and the cells returned to their respective wells. The 
cells were incubated for 24 hrs under the same conditions 
as above and the supernatants harvested and maintained at 
-60°C until assayed (within 2 weeks).
Preparation of Con A Blasts
Peripheral blood mononuclear cells were collected as 
above and suspended to a final concentration of 2 X 
106/ml in complete media containing 5 ug/ml Con A. After 
incubation for 5 days under the same conditions as above, 
the cells were gently pelleted (200 X g for 10 min), 
washed once with PBS and suspended in complete media at a 
concentration of 2 X 106/ml.
IL-2 Assay
The Con A blasts (100 ul) were placed in wells of a 
96 well microtiter plate. Supernatants containing IL-2 
were thawed and two-fold dilutions prepared to 1:64. The 
dilutions were added to triplicate wells containing the 
blast cells and incubated for 36 hrs. The cells were
q
pulsed with 0.5 y.Ci [JH ]thymidine and harvested onto 
glass fiber disks 18 hrs later using a semi-automated 
cell harvester (Skranton Inc., Sterling, VA). The disks 
were dried overnight at 60°C and placed in scintillation 
vials to which was added 3 ml of scintillation cocktail 
(Fluoralloy™, Beckman Instruments, Fullerton, CA). The 
vials were placed in the dark overnight to minimize 
inherent chemiluminescence. Counts were made for 2 min 
on a Packard Tri-Carb 4640 beta counter (Packard 
Instrument Co., Downers Grove, IL).
Statistical Analysis
Wilcoxon's rank sum test was used to identify 
diffrences using a dilution (1:4) which gave the highest 
blast cell proliferative response. A difference 
was considered significant at P<0.05.
Results
Con A blast proliferation induced by IL-2 containing 
supernatants was significantly (P<0.05) lower for 
infected cattle versus non-infected cattle with respect 
to Con A stimulation before sensitization (table 1), and 
after sensitization (table 2). The Con A, johnin, and 
PPD responses in the infected group was significantly 
(P<0.05) higher than the media control within that group 
before and after sensitization. Proliferative responses
obtained from non-infected and infected animals were 
highest with Con A stimulation. No significant (P>0.05) 
effect was seen with supernatants obtained by KLH 
stimulation in both groups before sensitization. The 
infected group showed significant differences between 
johnin and tL bovis PPD when compared to the non-infected 
group after sensitization. There was no significant 
(P>0.05) difference in the results obtained post­
sensitization in the infected group (table 2). The non- 
infected cattle had significantly (P<0.05) increased IL-2 
production in response to KLH, johnin, and bovis PPD 
after sensitization. No significant (P>0.05) alteration 
was observed in the Con A response after sensitization in 
the non-infected group. The KLH, johnin, PPD, and Con A 
responses were significantly (P<0.05) greater in the non- 
infected group in comparison to the infected group after 
sensitization. Sensitization was confirmed in the non- 
infected cattle by positive migration inhibition, 
lymphocyte stimulation, and skin test responses to the 
sensitizing antigens. The infected group failed to 
become sensitized based on the same assays (Chapter 2).
Discussion
In addition to T-cell proliferation, IL-2 has several 
other known functions such as induction of lymphokine 
activated killer cells which efficiently lyse a variety
of autologous and allogeneic tumor cells.24
Enhanced cytotoxicity of human monocytes has also been
described as a function of IL-2.®'16
The ability of T-cells to produce IL-2 has not been
previously investigated in bovine paratuberculosis.
Comparisons of IL-2 production can be made with
other mycobacterial diseases in which this lymphokine has
been examined, such as in leprosy.10'13'19
Bovine paratuberculosis, like leprosy, often results 
in diffuse granulomatous disease.6,23 Lepromatous 
leprosy patients are known to have deficient T-cell 
responses to leprae but not to other antigens while 
patients with tuberculoid leprosy have strong T-cell 
responses to NL leprae.26/28 It was previously indicated 
that this unresponsiveness was related to a deficiency in 
IL-2 production and that proliferative responses to M. 
leprae could be induced by an IL-2-rich T-cell 
conditioned media.10 This finding was disputed when it 
was demonstrated that failure of T-cells from lepromatous 
patients to respond to leprae was due to a defective 
IL-2 receptor expression mechanism. Receptor expression 
was not reversed by IL-2 or IL-1 even though IL-1 had 
been shown to induce IL-2 receptor expression.13/10 
Another study showed that T-cell unresponsiveness to M. 
leprae could be reversed by incubation of the T-cells in 
simple media in the abscence of leprae antigen for 48
1 fthrs. ° This phenomenon was explained by the induction 
of a CD4+ suppressor cell by leprae.
Cattle with paratuberculosis, in contrast to human 
patients with lepromatous leprosy, have positive, 
although variable, lymphocyte proliferative responses 
with in vitro exposure to johnin and other mycobacterial 
antigens.4'**'*2 it is only in the terminal stages of 
the disease when non-specific anergy is present that 
indicators of cell mediated immunity such as skin 
reactivity are diminished.® The criteria (weight loss and 
intermittant diarrhea of one year duration) used in this 
experiment to stage the animals with respect to disease 
spectrum does not reflect immune status of the host. 
Whether chronically infected and anergic animals or 
recently infected animals respond similarly with respect 
to IL-2 production is not known.
These data indicate that cattle with chronic bovine 
paratuberculosis have a decreased capacity to produce IL- 
2 in response to Con A and sensitizing antigens. Human 
IL-2 production can be inhibited by muramyl dipeptide, a 
known constituent of mycobacteria*4'*® The mechanism of 
this suppression has been shown to be mediated by 
suppressor T-cells and prostaglandins, ie, PGE2.*4'*5 
Muramyl dipeptide inhibition of Con A induced blood 
mononuclear cell proliferation was due at least in part 
to suppression of IL-2.*4'*® The suppression of IL-2 in
cattle with paratuberculosis may be due to mycobacterial 
components such as muramyl dipeptide or other soluble 
products derived from the tremendous number of organisms 
present in vivo. Alternatively, these and other 
mycobacterial constituents or products may induce 
suppressor substances which inhibit lymphocyte reactivity 
as described for lepromatous leprosy2^'26.
Table 1. Mean Con A Blast Proliferative Responses By
Blood Mononuclear Cell Supernatants Containing IL-2 
Before Sensitization
Infected Non-infected
Antigen cpma SIb cpm SI
Media 750 1.00 976 1.00
PPD 3,773 5.03*e 1,497 1.53
johnin 4,477 5.96*e 1,605 1.64
KLH 978 1.30 1,821 1.87
Con A 8,675 11.56*e 30,331 31.08*
aRepresents the mean cpm of triplicate assays from
the 3 infected cattle SD did not exceed 10% of the
mean. Only data from the dilution which gave the
highest cpm is shown (1:4).
bThe mean stimulation index was calculated by dividing 
the mean of each antigen cpm by the mean of the media 
control from each animal.
P<0.05, media comparison. 
eP< 0.05, group comparison.
Table 2. Mean Con A Blast Proliferative Responses By
Blood Mononuclear Cell Supernatants Containing IL-2 
After Sensitization
Infected Non- Infected
Antigen cpma SIb cpm SI
Media 1,116 1.00 835 1.00
PPD 5,267 4.72 7,997 9.57*e
johnin 6,003 5.38 9,815 11.75*e
KLH 1,139 1.02 10,363 12.41*e
Con A 8,897
•Ig
7.97 22,570 27.03*8
Represents the mean cpm of triplicate assays from 
the 3 infected cattle. SD did not exceed 10% of the mean. 
Only data from the dilution which gave the highest cpm is 
shown (1:4).
bThe mean stimulation index was calculated by dividing 
the mean of each antigen cpm by the mean the media 
control for each animal.
*P<0.05, media comparison. 
eP<0.05, group comparison.
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CHAPTER 5
INCREASED PRODUCTION OF INTERLEUKIN-2 IN CATTLE WITH 
CHRONIC BOVINE PARATUBERCULOSIS BY DIALYZABLE LYMPH NODE 
EXTRACTS CONTAINING TRANSFER FACTOR
Abstract
Bovine transfer factor specific for Mycobacterium 
paratuberculosis and keyhole limpet hemocyanin was 
prepared from lymph node dialysates and administered to 
three cattle with chronic bovine paratuberculosis. 
Cutaneous delayed hypersensitivity, lymphocyte 
blastogenesis, migration inhibition, interleukin-1 
release and interleukin-2 production were measured in 
response to M^ bovis PPD, johnin, and keyhole limpet 
hemocyanin before and after treatment with the transfer 
factor. There was no change in cutaneous delayed 
hypersensitivity after transfer factor treatment. No 
alterations in histopathologic features of pre- and post­
treatment sections of ileum were noted. Transfer factor 
treatment increased inhibition of migration of 
mononuclear cells and interleukin-2 production to johnin 
and KLH. There was no effect on lymphocyte blastogenesis 
and release of interleukin-1 by blood monocytes.
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These data suggest that cattle with chronic bovine 
paratuberculosis may benefit from transfer factor therapy 
and that the effects of transfer factor are partially 
mediated by an increase in interleukin-2 production.
Introduction
Bovine paratuberculosis is a chronic wasting disease 
produced by enteric infection with Mycobacterium 
paratuberculosis.12 Persistance of disease results from 
inability of the infected host to rid itself of the 
infection. This implies that there is a defect in cell 
mediated immunity. Blood monocytes and monocyte-derived 
macrophages from non-infected cattle have been shown to 
be unable to effectively kill the organism and allow 
intracellular proliferation.3'48 A deficient T-cell 
response (decreased killer cell activity and interferon 
production) could explain why infected cattle cannot 
eliminate the organism. It has been suggested that 
cattle with paratuberculosis may benefit from transfer 
factor (TF) therapy.24
Since the discovery of TF by Lawerence,26,27 viafcie 
leukocytes, leukocyte extracts, or dialysates of 
leukocyte extracts have been used to transfer delayed 
hypersensitivity to previously unsensitized individuals. 
Some of the clinical syndromes treated with transfer 
factor have included cancer immunotherapy,33'39 internal
93
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parasitism, lupus erythematosus, sarcoidosis, 
vaccinia,^ coccidiomycosis,^ tuberculosis,44
7
lepromatous leprosy , and recently intestinal 
cryptosporidiosis in patients with human immunodeficiency 
virus infections.24 These treatment results have been 
variable, although often promising.
Leukocyte lysates which contain inducer factors 
and suppressor factors have been obtained from T-helper
Of)
and T-suppressor cells, respectively. u Much of the 
variability noted in clinical applications has probably 
been due to the fact that the crude lysates contained 
mixtures of both factors.14'21'28,29 The suppressor 
factor has been used for the modulation of diseases such as 
lupus erythematosis and autoimmune thrombocytopenic 
purpura characterized by an undesirable immune 
response.4,20
Certain chemical and biological properties of TF have
O 0
been well documented. u In dialysates from human cells 
the active component is usually present in the 3.5 to 
12kD molecular weight range, and has been shown to bind 
to specific antigen and anti-la antibody.^ The inducer 
factor is absorbed by T-suppressor cells and
C.
macrophages. Bovine TF specific for Mycobacterium 
tuberculosis PPD has been characterized as an 
oligoribonucleopeptide with a molecular weight of between 
1.1 to 3.0kD.44 It has been postulated that TF may be a
dialyzable fragment of a T-helper cell receptor which 
equips the non-committed immunocyte with an antigen 
binding moiety.30
The duration of effect of treatment with TF has not 
been well documented in every case. In a study using 
TF as a preventative measure for varicella-zoster virus 
infection, it was found that antibody titers of TF- 
treated patients developed after virus exposure and 
remained as high as those in infected individuals for 17 
months.^3 The TF-treated group also had an active cell 
mediated immunity for the same period of time as 
demonstrated in vitro and by skin tests.
The effect of TF has not been previously evaluated in 
bovine paratuberculosis, but its effect on other 
mycobacterial diseases has been examined. Lepromatous 
leprosy patients were evaluated using TF which was 
prepared from donors selected on the basis of positive 
skin reactivity and in vitro lymphocyte responses.^ 
Infected recipients were initially negative to skin tests 
with lepromin. After administration of TF the recipients 
became skin test positive after the first or third days.^ 
In vitro lymphocyte blastogenesis results were not 
altered. The recipients experienced erythema of the 
cutaneous lesions and occasionally fever. There was no 
alteration in histologic characteristics of the lesions 
when compared to pre-TF lesions. The majority of the
recipients reverted to a skin test negative status about 
25 months after TF administration. These changes, 
although short-lived are extremely promising when it is 
considered that only one dose of TF was given. In 
patients with tuberculosis which was unresponsive to 
conventional tuberculostatic drugs, TF has been an 
important adjunct in therapy. 44,47
Materials and Methods 
Animals
Three naturally infected Brahman cross-bred cattle 
were donated to the Louisiana State University Veterinary 
Teaching Hospital by Louisiana cattle producers. The 
cattle were confirmed as positive for paratuberculosis by 
ileal and mesenteric lymph node biopsies and positive
A C
ELISA test results. ° The cattle were housed on concrete 
and fed Bermuda grass hay ad libitum. Two healthy 
Brahman calves (180 kg body weight) were purchased from a 
local stockyard for production of transfer factor.
Experimental Design
Biopsies of the ileum and and mesenteric lymph nodes 
were taken from each animal and the surgical sites 
allowed to heal for at least three weeks. Assays were 
performed for IL-1, IL-2, migration inhibition factor 
(MIF), lymphocyte blastogenic (LB) responses and 
cutaneous hypersensitivity in response to KLH, ML bovis 
PPD and johnin prior to treatment with transfer factor. 
Transfer factor was administered weekly for three weeks. 
At the end of the treatment period all assays were 
repeated and necropsies performed.
Skin Testing
The cervical area of each cow was clipped and double 
skin thickness measured prior to injection. Intradermal 
injections of 0.2 ml containing 1000 ug johnin, M. 
bovis PPD and KLH in PBS were given to each cow. For a 
negative control PBS was used. The change in double skin 
thickness was recorded after 48 hrs. The cattle were 
retested using the contralateral cervical area after 
transfer factor treatment.
Media and Reagents
The medium used for most assays consisted of RPMI 
1640 (GIBCO Laboratories, Chargin Falls, OH) supplemented 
with 4 mM L-glutamine and 10% fetal calf serum (FCS)
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without antibiotics (complete culture medium, CCM).
Dulbecco's MEM (GIBCO Laboratories, Chargin Falls, OH) 
was used in the migration inhibition assay. Phosphate- 
buffered saline (PBS), pH = 7.4, was used as a washing solution. 
Phytohemaglutinin (PHA), Cocanavalin A (ConA), keyhole 
limpet hemocyanin (KLH) (Sigma Chemical Co., St. Louis,
MO), johnin and Mycobacterium bovis (M. bovis) PPD 
(Veterinary Services Laboratory, Ames, IA) were diluted 
to appropriate concentrations (as determined by previous 
dose response trials) in CCM or PBS. Freshly prepared 
[^H]thymidine in CCM was used to assess proliferative 
responses in IL-1, IL-2 and LB assays. Mycobacterium 
paratuberculosis bacterin (Fromm Laboratories, Grafton,
WI) and KLH in Freund's incomplete adjuvant (Sigma 
Chemical Co., St. Louis, MO) were used to innoculate the 
donor calves for transfer factor preparation. All assays 
were performed before and after transfer factor 
treatment.
Blood Mononuclear Cells
Heparinized whole blood was collected by 
venapuncture and diluted 1:1 with (PBS). An equal volume 
of Histopaque-1.083 (Sigma Chemical Co., St. Louis, MO) 
was slowly injected underneath the blood using a 6 in, 18 
ga needle. The blood-Histopaque gradient was centrifuged 
at 1000 X g for 45 min and the mononuclear cell band at
the interface was removed and the cells washed three 
times with PBS. Platelet contamination was minimized by 
differential low speed centrifugation during washing (250 
X g for 10 min). The cells were suspended in complete 
medium to a final concentration of 2-5 X 106/ml depending 
on the assay to be performed. Cell viability was >95% 
using trypan blue exclusion.
Preparation of Adherent Cells for IL-1
Gradient-separated mononuclear cells were suspended 
in CCM at a concentration of 5 X 10^/ml. The cells were 
incubated in a 75 cm2 plastic culture flask (15 to 20 ml 
per flask) for 1 h. Non-adherent cells were removed by 
vigorously washing 5 times with PBS. Adherent cells were 
removed using a plastic cell scraper (Costar, Cambridge, 
MA) and suspended in CCM containing 2% FCS at a 
concentration of 1 X 106/ml (trypan blue exclusion showed 
a viability of >90%). The recovered cell suspension 
consisted of >95% monocytes with slight platelet 
contamination. Aliqouts of adherent cells (1ml) were 
placed in wells of a 24 well plate (Corning Glass Works, 
Corning, NY).
Preparation of IL-1 Containing Supernatants:
To 1 ml aliquots of adherent cells from each animal
was added an equal volume of one the following; media 
with 2% FCS, 50 ug/ml johnin, 50 ug/ml M^ bovis PPD, 50 
ug/ml KLH, and 20 ug/ml LPS. Cells were cultured for 24 
hrs at 37°C and 5% CC>2. Supernatants were harvested and 
maintained at -60°C until assayed (within 2 weeks).
IL-1 Assay:
The assay for IL-1 followed the guidelines as 
reviewed by Gearing, et al1^ with minor modifications. 
Adherent cell supernatants were thawed and serial two­
fold dilutions were made with media to 1:64. The 
thymuses from 6 wk old C3H/HeJ mice (Jackson 
Laboratories, Bar Harbor, ME) were used in all assays. 
Each thymus was aseptically removed and teased apart in 5 
ml of CCM. The thymocytes and thymic tissue were allowed 
to sediment at 1 X g for ten minutes. About 4 ml of cell 
suspension were withdrawn and adjusted to a final 
concentration of 5 X 10^/ml in media containing 10% FCS 
and 1.5 ug/ml Con A. Viability assesed by trypan blue 
exclusion was >95%. Thymocytes in 100 ul of media were 
added to the wells of a 96 flatbottom well culture plate. 
An equal volume of diluted adherent cell supernatant was 
added to the thymocyte cultures. After incubation for 48 
hrs, 0.5 uCi/50ul [3H ]thymidine in CCM was added to each 
well. Cells were harvested after 18 hr onto glass fiber 
disks a semi-automated cell harvester (Skranton Inc.,
Sterling, VA). The disks were dried overnight at 60°C 
and placed in scintillation vials to which was added 3 ml 
of scintillation cocktail (Fluoralloy™, Beckman 
Instruments, Fullerton, CA). The vials were placed in 
the dark overnight to minimize inherent 
chemiluminescence. Counts were made for 2 min on a 
Packard Tri-Carb 4640 beta counter (Packard Instrument 
Co., Downers Grove, IL). All assays were performed in 
triplicate. Supernatants were intermittantly screened for 
interleukin-2 as described below. Interleukin-2 activity 
using this assay was negligible.
Preparation of IL-2 Containing Supernatants
Preparation and assay of IL-2 containing supernatants 
were performed by the method of Oldham et al88 with minor 
modification. Mononuclear cells were suspended in CCM 
at a concentration of 4 X 106/ml and 2 ml of cells were 
placed in wells of a 24 well plate (Corning Glass Works, 
Corning, NY). The cells from each animal were cultured 
with 200 y.1 CCM containing one of the following; 500 
ug/ml Con A, 100 ug/ml johnin, 100 ug/ml NL bovis PPD, 
100 ug/ml KLH or CCM without additive. The cells were 
incubated in a humidified atmosphere for 1 hr at 37°C 
with 5% CC>2. The cell suspensions were harvested and the 
cells washed once with PBS. The wells were rinsed twice 
with 3 ml of PBS and the cells returned to their
respective wells. The cells were incubated for 24 hrs 
under the same conditions as above and the supernatants 
were harvested and maintained at -60°C until assayed 
(within 2 weeks).
Preparation of Con A Blasts
Blood was collected from a single healthy cow and
used to prepare Con A blasts for each IL-2 assay.
Peripheral blood mononuclear cells were collected as
above and suspended to a final concentration of 2 X 
£
10°/ml in CCM containing 5 p.g/ml Con A. After incubation 
for 5 days under the same conditions as described above, 
the cells were gently pelleted (200 X g for 10 min), 
washed once with PBS and suspended in CCM at a 
concentration of 2 X 106/ml.
IL-2 Assay
The Con A blasts (100 y.1) were placed in wells of a 
96 well microtiter plate. Supernatants containing IL-2 
were thawed and two-fold dilutions prepared to 1:64. The 
dilutions were added to triplicate wells containing the 
blast cells and incubated for 36 hrs. The cells were 
pulsed with 0.5 uCi [-^ H]thymidine and harvested after 18 
hrs incubation. Scintillation counting was done as 
described above.
Lymphocyte Blastogenesis
Gradient-separated mononuclear cells were suspended 
in CCM at a concentration of 2 X 10®/ml and 100 ul 
aliquots were placed in the wells of a 96 flatbottom well 
plate. To triplicate wells was added 100 ul volumes of 
CCM with one of the following: 50 ug/ml johnin, 50 ug/ml 
M. bovis PPD, 30 ug/ml KLH, 25 ug/ml PHA, or CCM without 
additives. The cells were incubated for 72 hrs., pulsed 
with 0.5 uCi/50ul [®]thymidine, and collected after 18 
hrs and handled as described above.
Migration Inhibition Assay
A microagarose droplet assay as described by 
Harrington and Stastny was used with minor 
modifications.19 Cell pellets containing 10® gradient- 
separated mononuclear cells were combined with 100 ul of 
2 X Dulbecco’s MEM with 20% FCS and 100 ul of 0.4% 
agarose in distilled water. The cells, media and agarose 
were gently mixed and 1 ul droplets were placed in the 
center of the wells of a 96 flatbottom well plate. The 
plate was refrigerated (4°C) for 10 min prior to the 
addition of antigens. To triplicate wells 100 ul volumes 
CCM was added containing one of the following: 50 ug/ml 
johnin, 50 ug/ml M^ _ bovis PPD, 50 ug/ml KLH, 25 ug/ml PHA 
and CCM without additive. After 48 hrs incubation each 
well was photographed and a 5 X 7 print made. The two
most symmetrical droplets from each treatment were 
selected and the distance was measured from the edge of 
the droplet to the edge of the cell migration zone.
Three random measurements were made from each of the 
selected droplets and the mean and standard deviation 
were calculated. Data were expressed as % inhibition of 
migration: [(mean migration distance of media control) -
(mean migration distance of antigen)/(mean migration 
distance of media control)] X 100. A 20% inhibition of 
migration was considered a positive MIF assay reaction.-*-1
Preparation and Administration of Crude TF
Two calves were inoculated with 8.0 mg KLH in 
Freund's incomplete adjuvant and 1 ml Mycobacterium 
paratuberculosis bacterin (twice the manufacturers 
reccomended dose). After three weeks, sensitization was 
confirmed by positive (>5 mm increase) skin test 
reactivity to johnin and KLH. The calves were killed and 
prescapular, submandibular, prefemoral, popliteal, 
cervical, tracheobronchial, mesenteric, perirenal, and 
pelvic lymph nodes removed. The lymph nodes were minced 
and pressed through a 40 mesh screen. The resulting cell 
suspension (5 X 108/ml) was incubated in Hank's balanced 
salt solution for 4 hrs at which time the suspension 
became acidic. The supernatants were harvested and an 
Amicon DC-10 hollow fiber concentrator in dialysis mode
was used to collect the fraction which contained material 
of lOkD molecular weight and less (designated crude TF). 
This fraction was frozen in 10 ml aliquots and maintained 
at -60°C until use (within 5 weeks). Each infected 
animal was given 10 ml of crude TF subcutaneously at 
weekly intervals for three weeks.
Necropsy
Treated animals were killed and sections of intestine 
adjacent to the original biopsy site and a regional 
mesenteric lymph node were fixed in 10% neutral buffered 
formalin, embedded in methacrylate, sectioned, mounted on 
glass slides, and examined by light microscopy. 
Hematoxylin and eosin and acid-fast stained sections were 
examined in pre- and post-treatment tissues.
Statistics
Wilcoxon's rank sum test was used to compare data for 
the IL-1 and IL-2 assays. Lymphocyte blastogenesis, 
migration inhibition, and skin test data were compared 
with Student's t-test. Results were considered 
significant at P<0.05.
Results
The administration of TF had no effect on skin test
reactivity (P>0.05) in this experiment (table 1). 
Migration inhibition and IL-2 production were 
significantly increased (P<0.05) using KLH (figure 1) and 
johnin (tables 2 and 3, respectively). There was no 
difference in LB responses with johnin, KLH, and PHA 
before or after TF treatment (table 4). The high 
blastogenic responses and inhibition of migration in 
response to M^ bovis PPD noted before TF treatment were 
significantly (P<0.05) reduced (tables 2 and 4).
Increases (P<0.05) in IL-2 production were seen only with 
johnin and KLH, with no change in response to Con A and 
M. bovis were not affected. Production of IL-1 was 
unaffected (P>0.05) by administration of TF (table 5).
The cpm values and stimulation indices for IL-1 release 
were similar to those obtained previously (Chapter 3). 
Sections of ileum and mesenteric lymph node were similar 
before and after TF treatment. Both contained a marked 
granulomatous reaction in the lamina propria and 
submucosa. Moderate to marked numbers of acid-fast 
bacilli were present in macrophages and multinucleated 
giant cells (figures 2-5).
Discussion
The classic response of TF treatment is the transfer 
of cutaneous hypersensitivity to previously non- 
responsive i n d i v i d u a l s . 30 Mazahari et al have shown
that positive cutaneous delayed hypersensitivity in 
primates may no be apparent until at least 21 days after 
administration of TF although in vitro migration 
inhibition was positive between 2 and 14 days.26 This 
may account for negative skin test results in this 
experiment as skin test reactions were examined only at 
21 days after the onset of TF administration.
In general, lymphocyte blastogenesis and monocyte 
migration inhibition have been considered good correlates 
of in vivo cell mediated immunity transfered by 
^16,35,40^ some studies, however, indicate this not to 
be true.17,41. There has been poor agreement between 
lymphocyte blastogenesis and cutaneous hypersensitivity 
tests in TF recipients.10,16 Usually there is a positive 
skin test response with no alteration in lymphocyte 
transformation. Non-specific activities of TF which 
affect lymphocyte blastogenesis include augmentation or 
suppression of responses to antigens or 
mitogens.1/8,9,18,32,43
It is interesting to note that in this experiment a 
previously significant blastogenic response to bovis 
PPD was selectively suppressed after TF treatment even 
though the TF was not prepared from a known NN bovis 
responsive donor. Monocyte migration inhibition assays 
are usually considered a more appropriate in vitro assay 
for the evaluation of the TF effects,22 however some
reports indicate the unfractionated (crude) TF-containing 
preparations augment non-specific production of migration 
inhibition factor.2/25
Indirect evidence indicates that the T-cell is the 
target cell for As effector cell in cell
mediated immune responses is the monocyte or macrophage, 
it would be reasonable to expect that TF acting on the T- 
cell would modulate the monocyte and macrophage.
Transfer factor preparations have also been shown to 
elevate interferon levels.13 This may be the important 
communication link between the TF activated lymphocyte 
and the macrophage.
The ability of TF preparations to augment or suppress 
production of IL-1 and IL-2 has not been previously 
examined. The results of this experiment indicate that 
TF augments IL-2 production in response to specific 
antigens but does not increase the release of IL-1. A 
generalized (non-specific) increase in IL-2 production 
may account for the increased dermal hypersensitivity 
seen following TF administration, but would not account 
for antigen specificity. The increase in IL-2 noted in 
this experiment was seen only in response to antigens to 
which the TF was initially prepared.
The results of this study demonstrate a previously 
unreported effect of TF, an increased antigen-specific 
production of IL-2. Although cutaneous hypersensitivity
was not transferred and no lesion alterations were noted 
after treatment, the positive responses (increased IL-2 
and greater migration inhibition) indicate that cattle 
with chronic bovine paratuberculosis may benefit from a 
longer duration of treatment with specific TF.
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Table 1. Delayed Cutaneous Hypersensitivity 
in Mycobacterium paratuberculosis-Infected Cattle 
Treated With Transfer Factor
Pre-Treatment Post-Treatment
Change in Skin Change in Skin
Thickness (mm) Thickness (mm)
Antigen
Cattle 
#1 #2 #3 #1
Cattle
#2 #3
PPD 4.2 3.2 4.4 4.0 3.0 4.5
johnin 5.3 6.6 3.2 4.9 5.9 3.3
KLH 0.2 0.6 1.4 0.3 0.6 1.1
media 0.0 0.0 0.3 
mean+SD
0.1 0.0 0.1 
mean+SD
PPD 3.93+0.64 3.83+0.76
johnin 5.03+1.72 4.70+1.31
KLH 0.73+0.61 0.67+0.40
media 0.10+0.17 0.07+0.06
No significant difference after transfer factor treatment.
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Table 2. Mean Percent Inhibition of Migration 
in Mycobacterium paratuberculosis-Infected Cattle 
Treated with Transfer Factor
Antigen Pre-Treatment Post-Treatment
PPDb 43.2 + 5.5a 21.3 + 1.8
johnin 33.7 + 1.8 58.1 + 7.1*
KLHC 11.5 + 0.9 52.5 + 6.2*
aMean+SD.
^Derived from Mj_ bo vis. 
cKeyhole limpet hemocyanin. 
*P<0.05
Ill
Table 3. Mean Con A Blast Proliferative Responses By Blood 
Mononuclear Cell Supernatants Containing IL-2 
From Mycobacterium paratuberculosis-Infected Cattle
Treated With Transfer Factor
Pre-Treatment Post-Treatment
Antigen cpma SIb cpm SI
Media 512 1.00 680 1.00
PPD 1 ,522
sir
3.02 1289 1.92
johnin 2,668
*
5.30 9,977 14.66*e
KLH 634 1.31 3,763 5.55s
Con A 7,612 15.02 * 6,980 10.26
aRepresents the mean cpm of triplicate assays from
the 3 infected cattle SD is not greater than 10% of
the mean. <Only data from the dilution which gave the
highest cpm is shown (1:4).
bThe mean stimulation index was calculated by dividing 
the mean of each antigen cpm by the mean of the media 
control for each animal.
sir
P<0.05, media comparison. 
eP<0.05, group comparison.
Table 4. Mean Lymphocyte Blastogenesis 
in Mycobacterium partuberculosis Infected Cattle 
Treated With Transfer Factor
Pre-■treatment Post-treatment
Antigen cpm SIa cpm SI
media 857 1.0 642 1.0
PPDb 10,627 12.6 4,237 7.1
johnin 9,684 11.3 8,089 11.9
KLHC 1,885 1.9 1,219 1.7
PHAd 20,396 23.3 12,968 21.7
aThe mean SI was calculated by dividing the mean antigen 
cpm of triplicate assays from each of the 3 infected 
animals by the cpm of the media control. SD did not 
exceed 10% of the mean.
^Derived from M;_ bovis; ckeyhole limpet hemocyanin; 
dphytohemaglutinin.
All antigen and mitogen responses are significantly 
different than the media control (P<0.05). No 
differences are apparent between pre- and post­
treatment data.
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Table 5. Mean Mouse Thymocyte Proliferation By 
Monocyte Supernatants Containing IL-1 In The Presence 
Of Con A FromMtcobacterium paratuberculosis-Infected 
Cattle Treated With Transfer Factor
Pre-treatment Post-treatment
Antigen cpma SIb cpm SI
Media 9,343 1.00 11,022 1.00
PPD 10,177 1.13 11,674 1.02
johnin 10,622 1.20 9,980 0.90
KLH 13,234 1.37 12,609 1.15
LPS 22,701 2.39 21,655 2.01
aData expressed is the mean cpm of triplicate assays form 
the 3 animals in each group. SD is not greater than 10% 
of the mean. Only data of the dilution which gave the 
highest cpm is shown (1:8).
bThe mean stimulation index was calculated by dividing 
the mean of each antigen cpm by the mean the media 
control for each animal. SD did not exceed 10% of the 
mean.
P<0.05, media comparison.
Figure 1. Example of increased migration inhibition in 
response to keyhole limpet hemocyanin after transfer 
factor treatment. Media control (top); before treatment 
(center); after treatment (bottom).
Figure 2. Ileal biopsy specimen taken before transfer 
factor treatment. There is a marked accumulation of 
macrophages in the lamina propria and submucosa. HE, 200X.
Figure 3. Section of ileum taken adjacent to the initial 
biopsy site after transfer factor treatment. Lesions 
noted are similar to the pre-treatment section. HE, 200X.
Figure 4. Lymph node biopsy specimen taken before 
transfer factor treatment. There is a moderate to marked 
accumulation of macrophages in the cortex. HE, 200X.
Figure 5. Mesenteric lymph node specimen taken adjacent 
to the initial biopsy site after transfer factor 
treatment. The section is similar to the pre-treatment 
biopsy sample.
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CHAPTER 6
THE EFFECTS OF RIFABUTIN (ANSAMYCIN LM 427) IN CATTLE 
WITH CHRONIC BOVINE PARATUBERCULOSIS
Abstract
Three cattle with chronic paratuberculosis were 
examined for delayed cutaneous hypersensitivity, 
macrophage migration inhibition, lymphocyte 
blastogenesis, interleukin-1 production and interleukin-2 
production in response to johnin, bovis PPD, and 
Keyhole limpet hemocyanin before and after treatment with 
rifabutin. Rifabutin was administered orally at a dose 
of 1200 mg daily for 3 weeks. Sections of ileum and 
mesenteric lymph node were examined microscopically 
before and after treatment. By the end of the treatment 
period there was a significant increase in skin 
reactivity to johnin. No changes in skin reactivity were 
seen with the other antigens. There was no difference in 
interleukin-1 release, interleukin-2 production, 
blastogenesis and migration inhibition before and after 
treatment.
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Introduction
Bovine paratuberculosis is a chronic enteric
infection caused by Mycobacterium paratuberculosis which
results in diarrhea, weight loss and eventually
death. Treatment of affected cattle with
antimycobacterial agents, such as clofazimine, has
resulted in drug dependent remission of clinical signs,
however, the cattle continued to shed the organism in
feces even with prolonged duration of treatment (over 300 
7 ft 1 1 IQdays)''°'xx'x . Although a cure does not result from the
administration of clofazimine, it may be useful for the
treatment of valuable breeding stock.
Rifabutin (4-deoxo-3,4-[2-spiro-(N-isobutyl-4-
piperidyl)](1H)-imidazole(2,5-dihydro)-rifamycin S), a
semi-synthetic derivative of rifamycin S, was first
synthesized by Marsili et al.^ This agent and other
related compounds were found to have activity against
Mycobacterium tuberculosis and Mycobacterium avium-
complex organisms. It also has the advantage of a longer
half-life than other derivatives of rifamycin S, such as 
1 7rifampin. * Rifabutin has a broad spectrum of activity 
against gram-positive and gram-negative bacteria similar 
to rifampin.15 The compound has activity against 
rifampin-resistant strains of Mycobacterium tuberculosis 
presumably due to the difference in mechanism of action. 
Rifabutin interferes with DNA synthesis whereas rifampin
1 8inhibits DNA-dependent RNA polymerase. °
The in vivo use of Rifabutin has been primarily 
limited to experimental infections and AIDS patients 
concurrently infected with mycobacteria.5,6,12,14 
Recently, a colony of stumptail macaques was diagnosed as 
having Mycobacterium paratuberculosis infection with 
lesions similar to ruminant paratuberculosis.^-® Macaques 
treated with rifabutin showed dramatic improvement and 
treated animals remained in clinical remission for up to 
30 months post-treatment.
Rifabutin has not been previously evaluated as a 
potential therapeutic agent for bovine paratuberculosis. 
The purpose of this study was to evaluate the use of 
rifabutin in bovine paratuberculosis by the comparison of 
immunologic parameters and intestinal lesions after 
treatment.
Materials and Methods 
Animals
Three naturally infected Brahman cross-bred cattle 
were donated to the Louisiana State University Veterinary 
Teaching Hospital by local cattle producers. The cattle 
were confirmed positive for paratuberculosis by ileal and 
mesenteric lymph node biopsies and positive ELISA 
test results.2® The cattle were housed on 
concrete and fed Bermuda grass hay ad libitum.
Experimental Design
Biopsies of the ileum and mesenteric lymph nodes were 
taken from each animal and surgical sites allowed to heal 
for at least three weeks. Assays were performed for 
interleukin-1 (IL-1), interleukin-2 (IL-2), migration 
inhibition factor (MIF), lymphocyte blastogenic (LB) 
responses and cutaneous hypersensitivity in response to 
KLH, IL bovis PPD and johnin prior to treatment with 
rifabutin. Rifabutin was administered daily per os for 
three weeks. At the end of the treatment period the 
assays were repeated and necropsies performed.
Media and Reagents
The culture medium used for most assays consisted of 
RPMI 1640 (GIBCO Laboratories, Chargin Falls, OH) 
supplemented with 4 mM L-glutamine and 10% fetal calf 
serum (FCS) without antibiotics (complete culture medium, 
CCM). Dulbecco's MEM (GIBCO Laboratories, Chargin Falls, 
OH) was used in the MIF assay. Phosphate-buffered saline 
(PBS), pH = 7.4, was used as a washing solution. 
Phytohemaglutinin (PHA), Concanavalin A (Con A), keyhole 
limpet hemocyanin (KLH) (Sigma Chemical Co., St. Louis, 
MO), johnin and Mycobacterium bovis (M . bovis) PPD 
(Veterinary Services Laboratory, Ames, IA) were diluted
to appropriate concentrations (as determined by previous 
dose response trials) in CCM or PBS. Freshly prepared 
[JH]thymidine in CCM was used to assess proliferative 
responses in IL-1, IL-2 and LB assays. Rifabutin was a 
gift obtained from Adria Laboratories, Columbus, Ohio 
(Vernon Verhoeff).
Skin Testing
The cervical area of each cow was clipped and double 
skin thickness measured prior to injection. Intradermal 
injections of 0.2 ml containing 1000 y.g johnin, M. 
bovis PPD and KLH in PBS were given to each cow. For a 
negative control PBS was used. The change in double skin 
thickness was recorded after 48 hrs. The cattle were 
retested using the contralateral cervical area after 
transfer factor treatment.
Blood Mononuclear Cells
Heparinized whole blood was collected by 
venapuncture and diluted 1:1 with (PBS). An equal volume 
of Histopaque-1.083 (Sigma Chemical Co., St. Louis, MO) 
was slowly injected underneath the blood using a 6 in, 18 
ga needle. The blood-Histopaque gradient was centrifuged 
at 1000 X g for 45 min and the mononuclear cell band at 
the interface was removed and the cells washed three 
times with PBS. Platelet contamination was minimized by
differential low-speed centrifugation during washing (250 
X g for 10 rain). The cells were suspended CCM to a final 
concentration of 2-5 X 10^/ml depending on the assay to 
be performed. Cell viability was >95% using trypan blue 
exclusion.
Preparation of Adherent Cells for IL-1
Gradient-separated mononuclear cells were suspended 
in CCM at a concentration of 5 X 106/ml. The cells were 
incubated in a 75 cm^ plastic culture flask (15 to 20 ml 
per flask) for 1 h. Non-adherent cells were removed by 
vigorously washing 5 times with PBS. Adherent cells were 
removed using a plastic cell scraper (Costar, Cambridge, 
MA) and suspended in CCM containing 2% FCS at a
f.
concentration of 1 X 10 /ml (trypan blue exclusion showed 
a viability of >90%). The recovered cell suspension 
consisted of >95% monocytes with slight platelet 
contamination. Aliquots of adherent cells (1ml) were 
placed in wells of a 24 well plate (Corning Glass Works, 
Corning, NY).
Preparation of IL-1 Containing Supernatants:
To 1 ml aliquots of 1 X 106 adherent cells/ml from 
each animal was added an equal volume of one of the 
following; CCM with 2% FCS, 50 ug/ml johnin, 50 y.g/ml M. 
bovis PPD, 50 p.g/ml KLH, and 20 ug/ml LPS. Cells were
cultured for 24 hrs at 37°C with 5% C02 and 100% 
humidity. Supernatants were harvested and maintained at 
-60°C until assayed (within 2 weeks).
IL-1 Assay:
The assay for IL-1 followed the guidelines as 
reviewed by Gearing, et al^ with minor modifications. 
Adherent cell supernatants were thawed and serial two­
fold dilutions were made with CCM to 1:64. The thymuses 
from 6 wk old C3H/HeJ mice (Jackson Laboratories, Bar 
Harbor, ME) were used in all assays. Each thymus was 
aseptically removed and teased apart in 5 ml of CCM. The 
thymocytes and thymic tissue were allowed to sediment at 
1 X g for ten minutes. About 4 ml of cell suspension was 
withdrawn and adjusted to a final concentration of 5 X 
106/ml in CCM containing 1.5 ug/ml Con A. Viability 
assessed by trypan blue exclusion was >95%. Thymocytes 
in 100 p.1 of CCM were added to the wells of a 96 
flatbottom culture plate. An equal volume of diluted 
adherent cell supernatant was added to the thymocyte 
cultures. After incubation for 48 hrs, 0.5 u.Ci/50ul 
[ H ]thymidine in CCM was added to each well. Cells were 
harvested after 18 hr onto glass fiber disks using a 
semi-automated cell harvester (Skranton Inc., Sterling, 
VA). The disks were dried overnight at 60°C and placed 
in scintillation vials to which was added 3 ml of
scintillation cocktail (Fluoralloy™, Beckman 
Instruments, Fullerton, CA). The vials were placed in 
the dark overnight to minimize inherent 
chemiluminescence. Counts were made for 2 min on a 
Packard Tri-Carb 4640 beta counter (Packard Instrument 
Co., Downers Grove, IL). All assays were performed in 
triplicate. Supernatants were intermittently screened for 
IL-2 as described below.
Preparation of IL-2 Containing Supernatants
Preparation and assay of IL-2 containing supernatants 
were performed by the method of Oldham et al^3 with minor 
modification. Mononuclear cells were suspended in CCM at 
a concentration of 4 X 10®/ml and 2 ml of cells were 
placed in wells of a 24 well plate (Corning Glass Works, 
Corning, NY). The cells from each animal were cultured 
with 200 p.1 CCM containing one of the following; 500 
ug/ml Con A, 100 ug/ml johnin, 100 jig/ml Mk_ bovis PPD, 
100 ug/ml KLH or CCM without additive. The cells were 
incubated in a humidified atmosphere for 1 hr at 37°C 
with 5% C02. The cell suspensions were harvested and the 
cells washed once with PBS. The wells were rinsed twice 
with 3 ml of PBS and the cells returned to their 
respective wells. The cells were incubated for 24 hrs 
under the same conditions as above and the supernatants
harvested and maintained at -60°C until assayed (within 2 
weeks).
Preparation of Con A Blasts
Blood was collected from a single healthy cow and 
used to prepare Con A blasts for each IL-2 assay. 
Peripheral blood mononuclear cells were collected as 
above and suspended to a final concentration of 2 X 
106/ml in CCM containing 5 y.g/ml Con A. After 
incubation for 5 days under the same conditions as above, 
the cells were gently pelleted (200 X g for 10 min), 
washed once with PBS and suspended in CCM at a 
concentration of 2 X 106/ml.
IL-2 Assay
The Con A blasts (100 y.1) were placed in wells of a 
96 well microtiter plate. Supernatants containing IL-2 
were thawed and two-fold dilutions prepared to 1:64. The 
dilutions were added to triplicate wells containing the 
blast cells and incubated for 36 hrs. The cells were 
pulsed with 0.5 y.Ci [ ] thymidine and harvested 
after 18 hrs and prepared for beta counting as before.
Lymphocyte Blastogenesis
Gradient-separated mononuclear cells were suspended 
in CCM at a concentration of 2 X 10®/ml and 100 ul
aliquots were placed in the wells of a 96 well flat 
bottom microtiter plate. To triplicate wells was added 
100 yl CCM with one of the following: 50 yg/ml johnin, 50 
yg/ml bo vis PPD, 30 yg/ml KLH, 25 yg/ml PHA, and CCM 
without additive. The cells were incubated for 72 hrs., 
pulsed with 0.5 yCi/50yl [ ®H ]thymidine, and collected 
after 18 hrs and handled as described (Chapter 2).
Migration Inhibition Assay
A microagarose droplet assay as described by 
Harrington and Stastny was used with minor 
modifications.4 Cell pellets containing 10® gradient- 
separated mononuclear cells was add 100 yl of 2 X 
Dulbecco's MEM with 20% FCS and 100 yl melted agarose 
(SeaPlaque™, FMC Corporation, Rockland, ME) The cells, 
media and agarose were gently mixed and 1 y.1 droplets 
were placed in the center of the wells of a 96 flatbottom 
microtiter plate. The plate was refrigerated (4°C) for 
10 min prior to the addition of antigens. To triplicate 
wells 100 y.1 CCM was added containing one of the 
following: 50 yg/ml johnin, 50 yg/ml M^ bovis PPD, 50 
yg/ml KLH, 25 yg/ml PHA and CCM without additive. After 
48 hrs incubation each well was photographed and a 5 X 7 
print was made. The two most symmetrical droplets from 
each treatment were selected and the distance from the 
edge of the droplet to the edge of the cell migration
zone was measured. Three random measurements were made
from each of the selected droplets and the mean and
standard deviation were calculated. Data were expressed
as % inhibition of migration: [(mean migration distance
of media control) -(mean migration distance of
antigen)/(mean migration distance of media control)] X
100. A 20% inhibition of migration was considered a 
1positive test.
Administration of Rifabutin
The cattle were each given 1200 mg rifabutin orally 
in gelatin capsules once daily for 21 days.
Necropsy
Treated animals were killed and sections of intestine 
adjacent to the original biopsy site and a regional 
mesenteric lymph node were fixed in 10% neutral buffered 
formalin, embedded in methacrylate, sectioned, mounted on 
glass slides, and examined by light microscopy. 
Hematoxylin and eosin and acid-fast stained sections were 
examined in pre- and post-treatment tissues.
Statistics
IL-1 and IL-2 production was compared using 
Wilcoxon's rank sum test. Migration inhibition, 
lymphocyte blastogenesis, and skin test data were
compared with Student's t-test. Results were considered 
significant at P<0.05.
Results
The delayed cutaneous hypersensitivity reaction to 
johnin significantly (P<0.05) increased after rifabutin 
treatment with no difference (P>0.05) in response to the 
other antigens (table 1). There was a slight increase 
(P>0.05) in IL-2 production to johnin stimulation, but no 
change was noted with the other antigens (table 2). No 
difference (P>0.05) in IL-1 release was observed before 
and after treatment (table 3). The cpm values and 
stimulation indices were similar to those previously 
obtained (chapter 3). There was a slight increase 
(P>0.05) in lymphocyte blastogenic responses with johnin 
(table 4). No alterations were found in migration 
inhibition before and after treatment (table 5). No 
histologic alterations were seen in sections of ileum and 
mesenteric lymph node after treatment (Figures 1-4). A 
marked granulomatous inflammatory reaction in the lamina 
propria and submucosa was observed. Macrophages and 
multinucleated giant cells contained variable numbers of 
acid-fast bacilli.
Discussion
Treatment with rifabutin produced a positive increase
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in cutaneous delayed hypersensitivity to johnin. A 
possible explanation for this increase is that perhaps 
there was an increase in mycobacterial death releasing 
internal bacterial antigens important in delayed 
hypersensitivity reactions. An increase in bacterial 
death could not be substantiated on the basis of the 
tissue sections examined, because only pre- and post­
treatment ileum and mesenteric lymph node sections were 
examined. The extent of tissue involvement before 
treatment was not determined. A second explanation may 
be that rifabutin itself increased the cutaneous response 
by directly affecting lymphocyte or accessory cell 
function. Lastly, it may be that rifabutin had a 
bacteriostatic effect resulting in a decrease in 
production of soluble substances from mycobacteria which 
inhibit skin test reactivity.
The trend of increased lymphocyte blastogenic 
responses to johnin may be a reflection of a similar 
trend in IL-2 production since IL-2 is known to increase T- 
cell proliferation in response to mitogen.17 This trend 
appears to suggest that cell-mediated immune responses 
are being partially restored. Additional trials with 
rifabutin in cattle with paratuberculosis may help to 
validate this observation.
The duration and dosage of rifabutin in this 
experiment was not sufficient to alter intestinal
and mesenteric lymph node lesions. A qualitative 
assessment indicated a granulomatous inflammatory 
response with the presence of numerous acid-fast bacilli 
similar to pre-treatment biopsy specimens.
The absorption, deposition and pharmacokinetics of 
rifabutin in the ruminant are not known. These 
parameters should also be investigated in order to more 
clearly define the value of rifabutin in the treatment of 
bovine paratuberculosis.
Table 1. Delayed Cutaneous Hypersensitivity
In Mycobacterium paratuberculosis-Infected Cattle
Treated With Rifabutin
PPD
johnin
KLH
media
Pre-Treatment 
Change in Skin 
Thickness (mm)
3.97+1.24
4.20+1.31
0.30+0.52
0.03+0.06
Post-Treatment 
Change in Skin 
Thickness (mm)
Antigen #1 #2 #3 #1 #2 #3
PPD 3.3 3.2 5.4 3.9 3.0 4.9
johnin 4.4 5.4
00•(N 10.4
00•00 in•
KLH
o•o 0.9 0.0 o • U)
CM•o 0.4
media 0.0 0.1 0.0
o•o 0.2
o•o
mean+SD mean+SD
3.9 3+0.9 5 
8.90+1.45s 
0.30+0.10
0.06+0.12
Table 2. Mean Con A Blast Proliferative Responses By 
Blood Mononuclear Cell Supernatants Containing IL-2 
From Mycobacterium paratuberculosi-Infected Cattle 
Treated With Rifabutin
Pre-Treatment Post-Treatment
Antigen cpma SIb cpm SI
Media 980 1.00 1,113 1.00
PPD 2,341 2.44* 2,177
4g
2.13
johnin 3,870 3.89* 5,805
«fp
5.12
KLH 1,015 1.13 1,654 1.39
Con A 9,578 8.79 10,599 9.43
aRepresents the mean cpm of triplicate assays from
the 3 infected cattle . SD is not greater than 10% of
the mean. Only data from the dilution which gave the
highest cpm is shown (1:4).
bThe mean stimulation index was calculated by dividing 
the mean of each antigen cpm by the mean of the media 
control from each animal.
P<0.05, media comparison.
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Table 3. Mean Mouse Thymocyte Proliferation By 
Monocyte Supernatants Containing IL-1 In The Presence of 
Con A From Mycobacterium paratuberculosis-Infected Cattle
Treated with Rifabutin
Pre-treatment Post-treatment
Antigen cpma SIb cpm SI
Media 12,654 1.00 14,166 1.00
PPD 11,298 0.93 10,988 0.74
johnin 13,990 1.10 15,011 1.11
KLH 10,512 0.93 12,475 0.88
LPS 25,539 2.13 27,886 2.03
aData expressed is the mean cpm of triplicate assays form 
the 3 animals in each group. SD is not greater than 10% 
of the mean. Only data of the dilution which gave the 
highest cpm is shown (1:8).
bThe mean lation index (SI) was calculated by dividing 
the mean of each antigen cpm by the mean of the nedia 
control from each animal.
P<0.05, media comparison.
Table 4. Mean Lymphocyte Blastogenesis 
in Mycobacterium partuberculosis Infected Cattle 
Treated With Rifabutin
Pre- treatment Post- treatment
Antigen cpm SIa cpm SI
media 1,008 1.0 1,114 1.0
PPDb 12,499 12.8 14,593 13.2
johnin 10,886 10.3 14,259 11.9
KLHC 3,326 3.6 4,678 4.6
PHAd 18,547 19.1 21,946 20.7
aThe mean SI was calculated by dividing the mean antigen 
cpm of triplicate assays from each of the 3 infected 
animals by the cpm of the media control. SD did not 
exceed 10% of the mean.
^Derived from ML bovis; ckeyhole limpet hemocyanin; 
dphytohemaglutinin.
All antigen and mitogen responses are significantly 
different than the media control (P<0.05). No 
differences are apparent between pre- and post­
treatment data.
Table 5. Mean Percent Inhibition of Migration 
In Mycobacterium paratuberculosis-Infected Cattle 
Treated With Rifabutin
Antigen Pre-Treatment Post-Treatment
PPDb 52.2 + 3.5a* 60.1 + 7.2*
johnin 43.3 + 3.9* 52.7 + 7.9*
KLH 14.2 + 1.8 11.5 + 6.6
aMean+SD.
^Derived from M. bovis.
cKeyhole limpet hemocyanin.
%Migration inhibition exceeded 98% with phytohemaglutinin 
in all assays.
Indicates a positive response (>20% inhibition).
Figure 1. Ileal biopsy specimen taken before rifabutin 
treatment. There is a marked accumulation of macrophages 
in the lamina propria and submucosa. HE, 20OX.
Figure 2. Section of ileum taken adjacent to the initial 
biopsy site after rifabutin treatment. Lesions noted are 
similar to the pre-treatment section. HE, 200X.
Figure 3. Lymph node biopsy specimen taken before 
rifabutin treatment. There is a moderate to marked 
accumulation of macrophages in the cortex. HE, 200X.
Figure 4. Mesenteric lymph node specimen taken adjacent 
to the initial biopsy site after rifabutin treatment.
The section is similar to the pre-treatment biopsy 
sample.
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CHAPTER 7
PRELIMINARY STUDIES WITH FERRITIN LABELING 
OF BOINE BLOOD MONOCYTES INFECTED WITH MYCOBACTERIUM
PARATUBERCULOSIS
Abstract
Bovine blood monocytes were pulse labeled with 
ferritin prior to infection with a field isolate of 
Mycobacterium paratuberculosis. Technical difficulty 
most likely related to fixation resulted in the absence 
of membranes in the cells examined. The cells did appear 
to phagocytize bacteria and take up the ferritin. 
Additional studies to accurately determine phagosome- 
lysosome fusion and killing ability of bovine blood 
monocytes is warranted.
Introduction
The intracellular fate of Mycobacterium 
paratuberculosis in cultured monocyte/macrophage systems 
has been previously examined. ^  These studies have 
shown that monocytes and monocyte-derived macrophages are 
efficient in phagocytizing the organism but fail to kill 
it or prevent its replication. Inhibition of phagosome-
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lysosome fusion is an important survival mechanism
q in 11 i qfor several mycobacterial species.
Many of the mononuclear phagocytes seen in the 
granulomatous lesions of bovine paratuberculosis probably 
represent recently recruited blood monocytes instead of 
tissue macrophages.^ This is supported by the finding 
that mycobacterial granulomas have a rapid turn-over 
rate,^ probably resulting from the influx of blood 
monocytes instead of from division of resident 
macrophages.3 Blood monocytes may therefore play a 
considerable role in the kinetics and maintenance of the 
granulomatous lesions in bovine paratuberculosis. For 
this reason, phagosome-lysosome fusion in blood monocytes 
infected in vitro with Mycobacterium paratuberculosis was 
qualitatively evaluated using ferritin to label 
lysosomes.
Materials and Methods 
Bacteria.
A field isolate of Mycobacterium paratuberculosis 
from a Brahman-cross bovine was
cultured from feces using Herrold's egg-yolk media 
containing 2 y.g/ml mycobactin J (Allied Laboratory, Ames, 
IA). Visible bacterial colonies were present after 6 
months incubation. The bacteria was subcultured in 
Middlebrook's 7H9 broth supplemented with OADC (Difco
Labs, Detroit, Michigan), Tween 80, and 2 y.g/ml 
mycobactin J. The organism was grown for approximately 4 
weeks, harvested by centrifugation, and washed with 
phosphate-buffered saline (PBS). The bacterial pellet 
was suspended in 15 ml of PBS and sonicated at 40% power 
for 30 seconds (Sonicator™ Model W-375, Ultrasonics, 
Inc.). The cell suspension was matched to a #4 McFarland 
standard equivalent to 12 X 10® bacteria/ml and 1 ml of 
cell suspension was added to 3 ml of RPMI 1640 containing 
10% fetal bovine serum and 4 mM L-glutamine resulting in 
a final concentration of 3 X 10®bacteria/ml. Viability 
was assessed at >95% by fluorescein diacetate-ethidium 
bromide staining.5
Preparation of Cells
Heparinized venous blood (30 ml) from a healthy 
adult cow was diluted approximately in half with PBS and 
layered onto 1.080 g/ml Ficoll 400-Sodium diatrizoate 
(Histopaque, Sigma Chemical Co., St. Louis, Missouri).
The blood and Ficoll gradient was centrifuged at 1000 X g 
for 45 minutes. The mononuclear cell layer removed and 
washed 3 times in PBS. Cell concentration was adjusted 
to 5 X 10® cells/ml in RPMI supplemented with 10% fetal 
bovine serum and 4mM L-glutamine. The cells were allowed 
to adhere in a 60 mm plastic petri dish for 1 hr. Non­
adherent cells were washed off and the adherent cell
layer removed by scraping and adjusted to 1 X 106 cells 
in media. The cell suspension (3 ml) was allowed to re- 
adhere in a 60 mm petri dish for 1 hr before ferritin 
labeling.
Ferritin Labeling
A ferritin (equine spleen) solution (20 mg/ml)
(Sigma Chemical Co., St. Louis, Missouri) was prepared in 
PBS containing 2% fetal bovine serum. The media from the 
adherent cells was removed and stored in a sterile 
container. The ferritin solution (4 ml) was added to the 
petri dish containing the cells and incubated at 37°C for 
3 hrs in the presence of 5% CO2. The ferritin solution 
was removed and the cells washed 3 times with PBS. The 
original culture media was then returned to the petri 
dish and incubated an additional 3 hrs.
Addition of Bacteria to Monocytes
The bacterial suspension (2 ml), as described above, 
was added to the cells and incubated for 3 hrs. After 
incubation, non-phagocytized bacteria were removed by 
washing with PBS.
Electron Microscopy
The adherent cells were fixed to the petri dish with 
cold 3% glutaraldehyde in 0.1% sodium cacodylate buffer
(pH = 7.4) for one hour. The cells were then removed by 
scraping from the petri dish, washed twice in 0.1 M 
cacodylate buffer containing 5% sucrose, and gently 
pelleted at 200 X g. One drop of melted 4% agarose was 
added to the cell pellet and gently mixed. The agarose 
was allowed to harden and was minced into < 1mm cubes. 
Post fixation was performed with 1% 0s04 in 0.1M 
cacodylate buffer (pH = 7.4) for one hour followed by 
dehydration in graded alcohols and propylene oxide. 
Infiltration and embedding was in Spurr's resin. Thin 
sections (60nm) were placed on uncoated copper grids and 
stained with uranyl acetate. The sections were viewed on 
a Zeiss EM-109 transmission electron microscope (Carl 
Zeiss Inc., Oberkochen, West Germany).
Results
Ferritin and bacteria were visible in all of the 
cells examined. No monocyte or bacteria-associated 
membranes were visible. The majority of the ferritin was 
present in round clumps, probably representing secondary 
lysosomes, and in vacuoles which also contained bacteria 
(Figures 1-4).
Discussion
Although ferritin labeling techniques for marking 
secondary lysosomes and morphologic evaluation of
phagosome-lysosome fusion has recently been
criticized,12'12 d'Arcy Hart has provided a good defense
for its use.7 The growth of intracellular parasites,
such as Listeria monocytogenes,6 Legionella
pneumophilia, and Toxoplasma gondii,20 is poor in
monocytes, however, other studies indicated that blood
monocytes and monocyte-derived macrophages supported the
91intracellular growth of Mycobacterium paratuberculosis, 
although macrophages by virtue of increased protein and 
lysozomal enzymes and increased phagocytic capacity are 
considered to be more effective than monocytes as killing 
cells in infectious granulomatous diseases.10'22
The methods used to process and stain the cells in 
this study did not allow accurate visualization of cell 
membranes. Therefore the formation of a true peri- 
bacillary electron transparent zone and phagosome- 
lysosome membrane fusion was not be assessed. This zone 
has been seen in macrophages infected with a variety of 
mycobacteria including M^ _ leprae,10 M. tuberculosis.  ^M. 
lepraemurium,2 M. avium,11 and M.
paratuberculosis.17,18,21 j^g been interpreted that 
It has been suggested that some bacterial surface 
component is responsible for the formation of the 
electron transparent zone and that this zone may 
represent a defense mechanism for intracellular survival 
of the bacilli.0'9 Recently evidence indicates that this
zone is probably not produced by bacterial surface 
components because coating the organism with immune sera 
does not inhibit formation of the zone.
The kinetics and morphogenesis of mycobacterial 
granulomas appears variable, but mycobacterial granulomas 
in general are considered to have a rapid turnover rate. 
Development into epitheliod lesions may require 4 to 22 
days depending upon the mycobacteria responsible for the 
lesion.1 High turnover granulomas have been described as 
being caused by non-toxic materials, and the macrophages 
contain relatively small amounts of the agent. This is 
the case in BCG and M;_ tuberculosis granulomas, but 
not in paratuberculosis. The lesions of paratuberculosis 
consist of epithelioid cells and giant cells which 
contain large numbers of bacteria. This is more 
indicative of low turnover granulomas.1
It would be interesting to speculate that fresh blood 
monocytes are active in phagosome-lysosome fusion and 
killing of paratuberculosis. This would account for 
prevention of bacterial dissemination and localization of 
the infection to the intestine and regional lymph nodes. 
These hypotheses can not be tested adequately until 
better morphologic and cultural data is obtained.
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Figure 1. The electron dense ferritin is present as 
round symmetrical clumps within the cell. (Uranyl 
acetate.)
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Figure 2. The ferritin appears as fine grains in what 
may be a phagocytic vacuole. (Uranyl acetate).
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Figure 3. A clump of ferritin adjacent to a structure 
resembling a bacterium. (Uranyl acetate)
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CHAPTER 8
CONCLUSIONS AND SUMMARY
Cattle with chronic paratuberculosis had positive 
lymphocyte blastogenic (LB) and migration inhibition 
factor (MIF) assay results using johnin and M^ _ bovis PPD. 
This indicated that these cattle have the ability to 
respond immunologically to these related antigens. The 
LB and MIF assay responses with johnin in infected cattle 
were similar to non-infected cattle after sensitization 
with WL_ paratuberculosis bacterin. This suggested that 
the in vitro response using these assays was of a normal 
magnitude. Infected cattle, in contrast to non-infected 
cattle, failed to develop positive skin tests and LB and 
MIF assay responses to keyhole limpet hemocyanin (KLH) 
after administration of a sensitizing dose of KLH in 
Freund's incomplete adjuvant. This lack of dermal 
response may have been related to the dose of KLH used or 
the minimum time allowed for a positive response to 
develop. Infected cattle apparently have the ability to 
respond immunologically to specific or cross-reactive 
antigen, yet fail to respond to a potent heterologous 
antigen. Failure of KLH responsiveness was not due to
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inherent defects in mononuclear cell proliferation 
capacity as demonstrated by a positive response to 
mitogen-induced proliferation. Sensitization of infected 
cattle with homologous antigen did not alter LB and MIF 
assay responses detected before sensitization. This 
indicated an uninducible steady-state of reactivity to M. 
paratuberculosis antigens. Skin test reactivity to 
johnin and M^ bovis PPD was significantly decreased by 
administration of paratuberculosis bacterin. It 
appeared that the cell type responsible for a positive 
skin test was made unreactive by high-dose antigen 
tolerance (desensitization).
Preliminary evidence suggested that phagosome- 
lysosome fusion in cultured blood monocytes may be 
assessed by pulse labeling with ferritin. The results 
obtained initially did not allow adequate interpretation, 
but suggested that phagosome-lysosome fusion had taken 
place. Additional studies using ferritin labeling 
appeared warranted.
Treatment of infected cattle with rifabutin 
significantly increased skin test reactivity to johnin. 
The reason for this may be that rifabutin damaged the 
bacilli and released previously hidden sensitizing 
antigens important in delayed hypersensitivity reactions. 
Damaged bacilli may have decreased their capacity to 
produce soluble substances which inhibit delayed
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hypersensitivity reactions. It may also be speculated 
that rifabutin had a direct effect on the cells 
responsible for cutaneous hypersensitivity. Although no 
significant differences in interleukin-1 (IL-1) release, 
interleukin-2 (IL-2) production, and LB and MIF assays 
were noted after rifabutin treatment, trends suggested 
that these parameters were increasing. Beneficial 
results may be obtained by longer treatment duration 
and/or a different dosage regimen.
The production of IL-2 by peripheral blood 
mononuclear cells induced by concanavalin A was 
significantly suppressed in infected cattle. These 
cattle produced significant levels of IL-2 in response to 
johnin and ML bovis PPD which was unaltered after 
administration of sensitizing doses of these antigens. 
Interleukin-2 production in response to KLH could not be 
induced by sensitizing doses of KLH in Freund’s 
incomplete adjuvant. Control cattle produced 
significantly greater amounts of IL-2 than infected 
cattle after sensitization. This indicated a defective 
IL-2 production mechanism in infected cattle. It can be 
speculated that this defect in IL-2 production results in 
inadequate numbers of paratuberculosis-reactive 
lymphocytes. Without reactive lymphocytes, killer cell 
and macrophage activation does not occur (discussed in 
Chapter 4). This may account for disease persistence in
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paratuberculosis.
Augmentation of lymphocyte function in infected 
cattle by specific transfer factor to KLH and M. 
paratuberculosis resulted in positive MIF assay responses 
and increased IL-2 production to these antigens. The 
ability of transfer factor to increase IL-2 production in 
response to specific antigens has not been previously 
reported.
Blood monocytes from infected spontaneously released 
high levels of IL-1 in the absence of antigenic or 
mitogenic stimulus. There is no direct evidence that 
indicates that monocytes or macrophages in the lesions 
react similarly. The spontaneous release of IL-1 by 
blood monocytes probably results from a chronic state of 
activation of these cells induced by mycobacterial 
products. There may also be a defective IL-1 regulatory 
mechanism in infected cattle. Whether this IL-1 detected 
by in vitro assays is a functional lymphocyte activating 
monokine in vivo is not known. It could be speculated 
that some of the clinical signs seen in infected 
cattle,such as cachexia, muscle wasting, and 
neutrophilia, might be attributed to high systemic levels 
of IL-1.
On the basis of the information gathered in this 
study the principle immunologic defect in chronic bovine 
paratuberculosis appeared to be a decreased ability to
produce IL-2 and that this defect is at the level of the 
T-lymphocyte. A potential failure to regulate IL-1 
release in blood monocytes was also discovered.
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